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Abstract
Aging	 is	characterized	by	a	progressive	 loss	of	physiological	 integrity,	while	cancer	
represents one of the primary pathological factors that severely threaten human lifes‐
pan and healthspan. In clinical oncology, drug resistance limits the efficacy of most 
anticancer	treatments,	and	identification	of	major	mechanisms	remains	a	key	to	solve	
this challenging issue. Here, we highlight the multifaceted senescence‐associated se‐
cretory	phenotype	(SASP),	which	comprises	numerous	soluble	factors	including	am‐
phiregulin	(AREG).	Production	of	AREG	is	triggered	by	DNA	damage	to	stromal	cells,	
which	passively	enter	senescence	in	the	tumor	microenvironment	(TME),	a	process	
that	remarkably	enhances	cancer	malignancy	including	acquired	resistance	mediated	
by	EGFR.	Furthermore,	paracrine	AREG	induces	programmed	cell	death	1	ligand	(PD‐
L1)	expression	in	recipient	cancer	cells	and	creates	an	immunosuppressive	TME	via	
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1  | INTRODUC TION
Although	 the	 development	 of	 advanced	 human	malignancies	 sub‐
stantially restrains the spectrum of therapeutic options, numerous 
data suggested that clinical failure is indeed intertwined with drug 
resistance	(Robey	et	al.,	2018).	To	date,	the	lack	of	a	sustained	treat‐
ment	 response	 is	 largely	 attributed	 to	 either	 intrinsic	 or	 acquired	
resistance	of	cancer	cells,	the	mechanisms	of	which	frequently	im‐
plicate	a	preexisting	tumor	microenvironment	(TME),	a	pathological	
entity that functionally supports the outgrowth of resistant clones 
even	in	clinical	settings	(Chen	et	al.,	2018;	Gandhi	&	Das,	2019).
Systematic investigation of drug resistance across tumor types, 
and even therapeutic categories, can enable novel insights into can‐
cer biology. Despite the initial response of tumors to most clinical 
regimens,	 the	 efficacy	 of	 subsequent	 interventions	 gradually	 van‐
ishes.	Off‐target	effects	of	cytotoxic	agents	frequently	trigger	irrep‐
arable damage in benign stromal cells surrounding the tumor foci 
(Faget,	Ren,	&	Stewart,	2019;	Sun,	Coppe,	&	Lam,	2018),	and	gener‐
ate a large number of senescent cells that display a senescence‐as‐
sociated	secretory	phenotype	(SASP;	Acosta	et	al.,	2008;	Coppe	et	
al.,	2008;	Kuilman	et	al.,	2008).	Although	the	SASP	can	favor	tissue	
homeostasis by supporting tissue repair, wound healing, and immu‐
nosurveillance	(Salama,	Sadaie,	Hoare,	&	Narita,	2014),	more	studies	
pinpoint	functional	 implications	of	the	SASP	in	age‐related	pathol‐
ogies	 (Childs	 et	 al.,	 2016;	 Jeon	 et	 al.,	 2017).	We	 and	 others	 have	
reported that secretion of a myriad of soluble factors including cyto‐
kines,	chemokines,	growth	factors,	and	proteases	generated	by	the	
SASP	promotes	chemoresistance	of	surviving	cancer	cells	after	early	
waves	 of	 administration,	 specifically	 in	 genotoxic	 settings	 (Gilbert	
&	 Hemann,	 2010;	 Obenauf	 et	 al.,	 2015;	 Sun	 et	 al.,	 2012).	 While	
the	SASP	is	entering	the	spotlight	of	intensive	research	in	multiple	
human	diseases,	it	remains	unknown	whether	specific	components	
of	the	full	SASP	spectrum	can	drive	cancer	resistance	as	major	forces	
under treatment pressure. Exploration of the functional mechanisms 
supporting	expression	of	 such	 “major”	 SASP	effectors,	 and	estab‐
lishment of therapeutic strategies to circumvent adverse effects of 
the	SASP	in	a	treatment‐damaged	TME,	represents	attractive,	prom‐
ising but challenging issues.
Distinct from conventional anticancer treatments including che‐
motherapy that have relatively limited efficacy and durability, immu‐
notherapy	takes	advantage	of	a	patient's	own	immune	system	and	
exhibits salient efficacy for many cancer types. Despite the unprec‐
edented tumor regression and long‐term survival benefit observed 
with	agents	against	programmed	cell	death	1	(PD‐1)	or	programmed	
cell	death	1	ligand	(PD‐L1),	a	large	portion	of	patients	do	not	bene‐
fit	 and	many	 responders	eventually	 relapse	 (Kim,	Herbst,	&	Chen,	
2018).	 Continued	 efforts	 to	 minimize	 resistance	 against	 immune	
checkpoint	blockade	 (ICB)	 require	a	clear	understanding	of	cancer	
resistance and should well precede current avenues using random 
combinations with available therapeutic modalities. Retrospective 
studies of patient populations have discovered that there are dif‐
ferent	types	of	TME,	whose	classification	can	be	improved	by	next‐
generation	technologies	to	inform	success	or	failure	of	current	ICB	
agents and encourage development of advanced immunotherapeu‐
tics	(Binnewies	et	al.,	2018).
The	 SASP	 can	 remodel	 the	 TME	 via	 paracrine	 actions	 and	 ac‐
celerate	disease	progression	 (Demaria	et	al.,	2017;	Obenauf	et	al.,	
2015).	Although	some	SASP	components	are	cytokines	or	chemok‐
ines	per	se,	such	as	IL‐8	and	CXCL3,	diverse	growth	factors	including	
amphiregulin	(AREG)	are	produced	by	senescent	human	stromal	cells	
(Coppe	et	al.,	2008;	Sun	et	al.,	2012),	suggesting	that	the	impact	of	
the	SASP	on	tumor	progression	could	be	complicated	and	multidi‐
mensional.	AREG,	an	epidermal	growth	factor	(EGF)	receptor	ligand,	
is implicated in multiple cancer types and potently enhances malig‐
nant	development	in	both	primary	and	metastatic	lesions	(Xu,	Chiao,	
&	Sun,	2016).	Using	a	colitis	and	tumor	vaccination	model,	a	group	
showed	 that	mast	 cell‐derived	AREG	potentiates	 the	 immunosup‐
pressive	competency	of	 regulatory	T	 (Treg)	cells,	 thus	establishing	
a	link	between	mast	cells	and	Treg	cells	in	the	TME	and	suggesting	
a potential value of perturbing the associated mechanism to im‐
prove	therapeutic	efficacy	of	EGFR‐targeting	agents	in	cancer	clin‐
ics	(Zaiss	et	al.,	2013).	However,	a	precise	cell	type‐specific	pattern	
of	 AREG	 production	 in	 response	 to	 anticancer	 treatments	 and	 its	
pathological implications in drug response remain poorly defined. In 
this	study,	we	discovered	the	unique	contribution	of	stromal	AREG	
to	 tumor	malignancy,	especially	drug	 resistance	acquired	 from	the	
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immune	 checkpoint	 activation	 against	 cytotoxic	 lymphocytes.	 Targeting	AREG	not	
only	minimized	 chemoresistance	of	 cancer	 cells,	 but	 also	 restored	 immunocompe‐
tency	when	combined	with	classical	chemotherapy	in	humanized	animals.	Our	study	
underscores	the	potential	of	in	vivo	SASP	in	driving	the	TME‐mediated	drug	resist‐
ance and shaping an immunosuppressive niche, and provides the proof of principle 
of	targeting	major	SASP	factors	to	improve	therapeutic	outcome	in	cancer	medicine,	
the success of which can substantially reduce aging‐related morbidity and mortality.
K E Y W O R D S
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treatment‐damaged	 TME,	 and	 demonstrated	 the	 potential	 of	 tar‐
geting	AREG	in	combination	with	classic	chemotherapy	to	improve	
therapeutic	index.	AREG	represents	both	a	soluble	factor	that	is	tar‐
getable	to	circumvent	advanced	conditions	including	acquired	resis‐
tance	against	both	conventional	and	ICB	treatments,	and	a	distinct	
SASP	biomarker	to	timely	monitor	the	in	vivo	response	of	the	TME	
in	clinical	settings.	Since	AREG	is	a	hallmark	 indicator	of	the	SASP	
development and holds both therapeutic and prognostic values, 
harnessing	such	a	“major”	TME	factor	in	synergy	with	conventional	
agents may represent a novel therapeutic paradigm to enhance pa‐
tient outcome in future clinics.
2  | RESULTS
2.1 | AREG expression increases in senescent 
human stromal cells produced by genotoxic 
treatments
Former	 studies	 showed	 that	 AREG	 is	 upregulated	 in	 response	 to	
diverse stimuli, but is mainly associated with immune cell popula‐
tions activated in type 2 inflammatory responses to restore tissue 
integrity	 and	 homeostasis	 (Zaiss,	 Gause,	Osborne,	 &	 Artis,	 2015).	
In	 cancer	 cells	 carrying	 EGFR	mutants	 such	 as	 T790M,	AREG	 ex‐
pression	is	markedly	elevated,	but	mostly	limited	to	lung	malignan‐
cies	 (Regales	et	al.,	2009;	Taverna	et	al.,	2017).	However,	 the	vast	
majority	 of	AREG	biology	 has	 been	 focused	 on	 immune	 and	 neo‐
plastic cells, leaving the tissue‐resident stroma that contains vari‐
ous	benign	cell	types	largely	overlooked,	particularly	their	dynamics	
in	clinical	conditions.	We	recently	 found	that	 the	prostate	stromal	
cell	line	PSC27,	comprising	mainly	fibroblasts	but	with	a	minor	per‐
centage of nonfibroblast cell lineages including endothelial cells and 
smooth	muscle	cells,	produces	a	large	number	of	SASP	factors	after	
exposure to cytotoxic insults, specifically genotoxic chemotherapy 
or	 ionizing	 radiation	 (Sun	et	al.,	2012).	Of	note,	AREG	emerged	as	
one	of	 the	major	SASP	factors	as	previously	demonstrated	by	our	
microarray	data	 (Figure	1a;	Sun	et	al.,	2012).	To	expand	the	study,	
we	 applied	 a	 subset	 of	 DNA‐damaging	 agents	 (DDA)	 including	
bleomycin	(BLEO),	mitoxantrone	(MIT),	and	satraplatin	(SAT),	and	a	
group	 of	 non‐DNA‐damaging	 agents	 (NDDAs)	 including	 paclitaxel	
(PTX),	docetaxel	(DTX),	and	vincristine	(VCR)	to	treat	stromal	cells.	
All	agents	caused	reduced	DNA	synthesis	(BrdU	incorporation)	and	
increased	 lysosomal	 activity	 (SA‐β‐Gal	 positivity),	 indicating	 typi‐
cal	cell	cycle	arrest	accompanied	by	cellular	senescence	(Figure	1b,	
c).	However,	only	the	DDA	group	induced	intensive	DDR	activities	
(Figure	 1d).	 Subsequent	 examination	 at	 both	 mRNA	 and	 protein	
levels	confirmed	the	inducible	nature	of	AREG	in	response	to	geno‐
toxic	stress,	a	process	accompanied	by	extracellular	release	(p < .01 
at	transcript	 level;	Figure	1e).	Notably,	AREG	transcript	expression	
largely	phenocopied	other	hallmark	SASP	factors	including	MMP1,	
WNT16B,	SFRP2,	MMP12,	and	IL‐8,	which	exhibited	a	gradual	incre‐
ment until approaching a platform within 7–8 days after treatment 
(p	<	.01	for	SFRP2,	MMP12,	and	IL‐8,	p	<	.001	for	others;	Figure	1f).	
Intracellular	expression	and	extracellular	secretion	of	AREG	protein	
largely paralleled its transcriptional expression, each manifesting a 
time‐dependent	increase	after	genotoxic	stress	(Figure	1g).
Expression assessment among several cell lines of prostate or‐
igin	 disclosed	 that	 stromal	 cells	 are	 indeed	 more	 AREG‐inducible	
than cancer epithelial cells, implying a special mechanism that sup‐
ports	AREG	production	in	prostate	stromal	cells	post‐DNA	damage	
(p < .01 for stromal, p	>	.05	for	most	cancer	epithelial	lines;	Figure	1h).	
The	responsiveness	to	genotoxicity	and	differential	expression	pat‐
tern between stromal and cancer epithelial lines were confirmed in 
an alternative group of cell lines of human breast origin, including 
a	stromal	 line	HBF1203	and	several	cancer	cell	 lines	 regardless	of	
their	malignancy	properties	 (Figure	S1a–e).	To	 further	expand,	we	
examined	 human	 diploid	 fibroblast	 (HDF)	 and	 mouse	 embryonic	
fibroblast	 (MEF)	 lines,	 and	 found	 a	 similar	DNA	damage‐inducible	
pattern	 of	 AREG	 (Figure	 S1f–i).	 The	 data	 consistently	 suggest	 an	
organ‐	or	tissue	type‐independent	nature	of	AREG	induction	upon	
cellular	senescence	in	response	to	genotoxic	stress.	We	also	noticed	
that	overexpression	of	AREG	itself	in	these	lines	was	insufficient	to	
induce	cellular	senescence	or	result	in	the	SASP	development,	sug‐
gesting limited influence of this soluble factor on stromal cell senes‐
cence	(Figure	S1f–i).
2.2 | Stromal AREG expression predicts adverse 
clinical outcome after chemotherapy
The	 in	 vitro	 findings	 prompted	 us	 to	 further	 determine	 whether	
AREG	is	produced	by	the	TME,	a	pathological	entity	that	comprises	
numerous	benign	stromal	cells.	We	investigated	the	biospecimens	of	
a	cohort	of	prostate	cancer	(PCa)	patients	who	developed	primary	
tumors	and	underwent	genotoxic	chemotherapy.	Surprisingly,	AREG	
was found significantly expressed in the prostate tissues of patients 
after	chemotherapy,	but	not	before	 (Figure	2a).	 In	 line	with	our	 in	
vitro	data,	upregulated	AREG	was	generally	localized	in	the	stroma,	
in sharp contrast to the adjacent cancer epithelium which had limited 
or no staining.
AREG	synthesis	in	patient	tissues	post‐	versus	prechemotherapy	
was	 quantitatively	 consolidated	 by	 a	 pre‐established	 pathological	
appraisal procedure that allowed precise assessment of a target 
protein	 expression	 according	 to	 its	 immunohistochemistry	 (IHC)	
staining	intensity	(p	<	.001;	Figure	2b).	Transcript	analysis	upon	laser	
capture	microdissection	(LCM)	of	cell	lineages	from	the	primary	tis‐
sues	 indicated	that	AREG	was	more	readily	 induced	in	the	stromal	
rather	than	cancer	cell	populations	(p < .001 vs. p	>	.05;	Figure	2c).	To	
substantiate	AREG	inducibility	in	vivo,	we	analyzed	a	subset	of	pa‐
tients whose pre‐ and postchemotherapy biospecimens were both 
accessible,	and	found	remarkably	upregulated	AREG	in	the	stroma,	
but not cancer epithelium, of each individual after chemotherapy 
(Figure	2d,e).	Further,	we	noticed	AREG	expression	dynamics	in	the	
damaged	TME	essentially	in	parallel	to	those	of	IL‐8	and	WNT16B,	
two	canonical	SASP	factors	(Figure	2f).	Expression	sites	of	these	fac‐
tors	were	largely	overlapping	with	those	of	senescent	cells	(p16INK4a+ 
and p21CIP1)	in	the	TME,	excluding	cancer	cells,	which	may	have	sur‐
vived	and	progressively	 repopulated	after	 therapy	 (Figure	2g;	Sun	
4 of 25  |     XU et al.
     |  5 of 25XU et al.
et	 al.,	 2012).	 Cellular	 senescence	was	 developed	 pronouncedly	 in	
the stromal compartment, which also includes immune cells such as 
a	 limited	number	of	macrophages.	The	correlation	between	AREG	
and	IL‐8/WNT16B	expression	in	the	damaged	TME	was	further	sub‐
stantiated by pathological evaluation of their expression scores in 
post‐treatment	patients	(Figure	2h,i).	More	importantly,	the	Kaplan–
Meier	analysis	of	PCa	patients	stratified	according	to	AREG	amount	
in tumor stroma suggested a significant but negative correlation 
between	AREG	protein	 level	and	disease‐free	survival	 (DFS)	 in	the	
treated	cohort	(p	<	.001,	log‐rank	test;	Figure	2j).
The	distinct	pathological	properties	of	AREG	were	reproduced	
by an extended study that recruited individual cohorts of human 
breast	cancer	(BCa)	patients	(p < .001, survival comparison by log‐
rank	test;	Figure	S2a‐i).	Of	note,	Cox	proportional	hazard	regression	
analyses of these patients indicated significant correlation of stro‐
mal	AREG	with	poor	cancer	survival	(Tables	S1–S4).	Thus,	our	data	
consistently	suggested	that	AREG	expression	in	tumor	stroma	acts	
as	an	SASP‐associated	independent	predictor	of	prognosis,	which	is	
exploitable	in	stratifying	the	risk	of	disease	relapse	and	clinical	mor‐
tality	of	post‐treatment	patients,	and	that	AREG	production	by	the	
stroma may have a causal role in tumor progression.
2.3 | Paracrine AREG generates oncogenic effects 
by activating EGFR‐mediated pathways in recipient 
cancer cells
We	next	examined	 the	effect	of	 stromal	AREG	on	PCa	cell	 lines	
via	co‐culture	with	conditioned	media	(CM)	derived	from	stromal	
cells,	 an	 assay	 involving	 PSC27	 sublines	 stably	 overexpressing	
or	 subsequently	 losing	AREG	 (Figure	 S3a).	Upon	 treatment	with	
the	CM	 from	AREG‐positive	 cells	 (PSC27AREG),	we	observed	 sig‐
nificantly	increased	proliferation	of	a	group	of	established	PCa	cell	
lines	including	PC3,	DU145,	LNCaP,	and	M12	(p	<	.01;	Figure	S3b).	
Indicative of advanced cell malignancy, the migration and invasion 
activities	 of	 PCa	 cells	 were	 considerably	 enhanced	 in	 the	 pres‐
ence	 of	 stromal	 AREG	 (p < .01 for most migration and invasion 
assays;	Figure	S3c,d).	However,	the	malignancy‐promoting	effects	
of	AREG	on	cancer	behaviors	were	almost	completely	abrogated	
upon	 AREG	 depletion	 from	 PSC27	 (Figure	 S3b–d).	More	 impor‐
tantly,	AREG	enhanced	the	resistance	of	PCa	cells	against	MIT,	a	
DNA‐targeting	 chemotherapeutic	 agent	 for	 human	malignancies	
including	 PCa	 (Bergstrom	 et	 al.,	 2017;	 Eisenberger	 et	 al.,	 2017;	
Figure	S3e).	To	further	confirm	the	contribution	of	AREG	to	cancer	
cell	phenotypic	alterations	by	 specifically	eliminating	AREG	pro‐
tein	itself,	we	generated	a	monoclonal	antibody	(AREG	mAb)	with	
high	 competency	 in	 recognizing	 free	AREG	 in	 culture	 conditions	
(Figure	S3f).	The	data	from	AREG	mAb‐relevant	assays	closely	re‐
sembled	those	from	AREG	knockdown	experiments	(Figure	S3b‐e),	
thus	excluding	the	possibility	that	AREG	itself	induces	expression	
of	other	SASP	factors	in	stromal	cells.
Further	analysis	indicated	that	MIT	induced	cleavage	of	caspase	
3	in	cancer	cells,	a	process	remarkably	weakened	by	AREG	but	re‐
versible	upon	elimination	of	AREG	from	stromal	cells	 (Figure	S3g),	
implying	that	AREG	drives	cancer	resistance	 largely	via	a	caspase‐
counteracting mechanism, which dampens caspase 3 activation by 
its	 self‐cleavage.	We	 further	 applied	 QVD‐OPH	 and	 ZVAD‐FMK,	
two	 potent	 pan‐caspase	 inhibitors,	 and	 PAC1	 and	 gambogic	 acid	
(GA),	two	caspase	activators,	to	 individually	treat	PC3	cells	before	
MIT	 exposure.	 Cell	 apoptosis	 was	 substantially	 attenuated	 when	
QVD‐OPH	or	ZVAD‐FMK	was	used,	even	in	the	presence	of	AREG	
(p	 <	 .001;	 Figure	 S3h).	 However,	 once	 the	 pro‐caspase‐activating	
compound	PAC1	or	GA	was	added	to	the	media,	apoptosis	index	was	
markedly	 increased,	 offsetting	 the	 anti‐apoptosis	 effect	 of	 AREG	
(p	 <	 .01	 in	 the	presence	of	AREG;	Figure	S3h).	 The	data	were	 re‐
produced	when	 docetaxel	 (DOC),	 another	 chemotherapeutic	 drug	
typically	inhibiting	microtubule	depolymerization,	was	applied	to	the	
system	(Figure	S3i).	Thus,	our	results	consistently	demonstrate	that	
stromal	 AREG	 perturbs	 caspase‐dependent	 apoptosis,	 underlying	
F I G U R E  1  Genotoxic	agents	induce	cellular	senescence	and	the	SASP	including	AREG.	(a)	Gene	expression	change	in	primary	normal	
human	prostate	stromal	cells	(PSC27)	profiled	by	microarray	analysis.	CTRL,	control.	BLEO,	bleomycin.	HP,	hydrogen	peroxide.	RAD,	ionizing	
radiation.	Red	arrow,	AREG.	Top	50	genes	are	displayed.	(b)	BrdU	staining	performed	7	days	after	treatment	of	PSC27	cells	by	different	
agents	including	paclitaxel	(PTX),	docetaxel	(DTX),	and	vincristine	(VCR)	as	non‐DNA‐damaging	agents	(NDDA),	with	bleomycin	(BLEO),	
mitoxantrone	(MIT),	and	satraplatin	(SAT)	applied	as	DNA‐damaging	agents	(DDA)	in	parallel	assays.	Top,	pictures	from	PTX	and	BLEO	
treatments shown as representative images of each agent type. Scale bars = 15 μm.	Bottom,	statistics	of	staining	positivity.	(c)	SA‐β‐Gal 
staining	of	PSC27	cells	treated	by	various	agents	depicted	in	(b).	Cells	were	stained	7	days	after	in	vitro	treatments.	Top,	representative	
images. Scale bars = 15 μm.	Bottom,	statistics	of	staining	positivity.	(d)	Immunofluorescence	staining	of	DNA	damage	foci	(DDR)	(γH2AX)	
of	PSC27	cells	treated	by	various	agents.	DDRs	were	quantitatively	classified	into	four	subcategories	including	0	foci,	1	~	3	foci,	4	~	10	foci,	
and	>10	foci	per	cell.	Top,	representative	images.	Scale	bars	=	15	μm.	Bottom,	comparative	statistics.	(e)	AREG	expression	after	treatment	
of	PSC27	cells	by	various	agents.	Cell	lysates	were	collected	for	measurement	7	days	after	treatment.	Top,	quantitative	RT–PCR	(qRT–PCR)	
assays,	signals	normalized	to	CTRL.	Bottom,	immunoblots.	IC,	intracellular;	CM,	conditioned	media;	GAPDH,	loading	control.	(f)	Time	course	
expression	of	representative	SASP	factors	(MMP1,	WNT16B,	SFRP2,	MMP12,	IL‐8,	and	AREG)	after	bleomycin	treatment.	Experimentally,	
qRT–PCR	assays	were	performed	with	stromal	cells	treated	with	50	μg/ml bleomycin and collected at a series of time points including 0, 1, 
3,	5,	7,	10,	and	15	day(s)	post‐treatment,	respectively,	which	are	represented	by	numerical	numbers	1,	2,	3,	4,	5,	6,	and	7	labeled	on	the	X‐
axis.	(g)	Immunoblot	analysis	of	PSC27	cells	collected	at	various	time	points	post‐treatment	with	bleomycin	to	reveal	the	expression	pattern	
of	AREG	at	protein	level.	IC,	intracellular;	CM,	conditioned	media;	GAPDH,	loading	control.	(h)	Comparative	analysis	of	AREG	transcript	
expression	in	stromal	cells	(PSC27)	versus	neoplastic	epithelial	cells	(M12,	PC3,	DU145,	LNCaP,	and	22RV1).	Top,	qRT–PCR	assays,	signals	
normalized	to	untreated	sample	per	cell	line.	Bottom,	immunoblots.	IC,	intracellular;	CM,	conditioned	media;	GAPDH,	loading	control.	Data	
are representative of three independent experiments. p	Values	were	calculated	by	one‐way	(b,	c,	e,	f,	h)	and	two‐way	(d)	ANOVA	(^p > .05; 
**p < .01; and ***p	<	.001).	Agilent	microarray	data	of	(a)	were	adapted	from	Sun	et	al.	with	permission	from	Nature	Medicine,	copyright	2012
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its resistance‐boosting capacity via paracrine influence on recipient 
cancer cells.
We	next	explored	the	mechanism	supporting	AREG	to	confer	
the	 pro‐survival	 advantage	 on	 cancer	 cells.	 Since	 AREG	 protein	
encompasses	an	EGF‐like	domain	(aa	141–181)	which	has	six	spa‐
tially conserved cysteines forming disulfide bridges and the 3‐
looped	structure	defining	the	EGF	family	(Berasain	&	Avila,	2014),	
we	first	determined	the	function	of	AREG	as	an	EGF‐like	growth	
factor	 via	 in	 vitro	 assays.	Upon	 treatment	 of	 PCa	 cells	with	 the	
CM	from	AREG‐expressing	PSC27	(PSC27AREG),	we	observed	rapid	
phosphorylation	of	EGFR	(Y845),	Akt	 (S473),	and	mTOR	(S2448),	
suggesting	 activation	 of	 the	 PI3K/Akt/mTOR	 pathway	 by	 AREG	
(Figure	 3a).	 Further,	 phosphorylation	 of	 Mek	 (S217/S221),	 Erk	
(T202/Y204),	and	Stat3	(S727)	was	identified,	indicating	simulta‐
neous	activation	of	a	MAPK	pathway	in	these	cells.	We	then	used	
tyrphostin	 AG1478,	 a	 selective	 receptor	 tyrosine	 kinase	 (RTK)	
inhibitor	 preferentially	 targeting	 EGFR	 (El‐Hashim	 et	 al.,	 2017).	
Upon	addition	of	AG1478,	AREG‐induced	EGFR	phosphorylation	
was	 abolished,	 with	 reduced	 activation	 of	 both	 Akt/mTOR	 and	
Mek/Erk/Stat3	 axes	 (Figure	 3a).	 Thus,	 AREG‐triggered	 activa‐
tion of these two signaling pathways was essentially mediated by 
EGFR,	although	functional	 involvement	of	other	RTKs	cannot	be	
excluded.	We	 next	 performed	 immunoprecipitation	 (IP)	 with	 an	
AREG‐specific	antibody	after	treatment	of	PCa	cells	with	AREG+ 
stromal	media.	A	strong	interaction	between	AREG	and	EGFR	was	
evidenced by the prominent signal in the precipitate pulled down 
by	 anti‐AREG	 rather	 than	 the	 control	 IgG,	 with	 IP	 signal	 much	
stronger	in	AREG+	CM‐treated	cells	than	control	(Figure	3b).
We	 interrogated	whether	AREG,	 a	 soluble	 factor	 expressed	 in	
the	 entire	 stromal	 SASP	 spectrum,	 generates	 remarkable	 effects	
on	 the	 phenotypes	 of	 stromal	 cells	 per	 se.	Of	 note,	 AREG	 deple‐
tion	 from	PSC27	cells	 neither	delayed	nor	 accelerated	 cellular	 se‐
nescence,	as	indicated	by	SA‐β‐Gal	assay	(Figure	3c).	However,	we	
noticed	 that	 AREG	 elimination	 from	 PSC27	 markedly	 dampened	
pathway	 activation	 induced	 by	 the	 full‐blown	 SASP	 of	 damaged	
stromal	 cells,	 suggesting	AREG	as	 a	 critical	 paracrine	 SASP	 factor	
that	 phosphorylates	 EGFR	 and	 engages	 multiple	 key	 intercellular	
signaling	molecules	in	recipient	cancer	cells	(Figure	S3j).	The	CM	of	
DNA‐damaged	PSC27	(PSC27‐BLEO)	increased	the	proliferation	by	
2.4‐	 to	3.2‐fold,	migration	by	2.3‐	 to	3.5‐fold,	and	 invasiveness	by	
2.5‐	to	3.4‐fold	of	PCa	cell	lines,	respectively,	while	AREG	clearance	
from	PSC27	significantly	reduced	the	capacity	of	stromal	CM	in	en‐
hancing	the	malignant	phenotypes	of	PCa	cell	lines,	with	a	reduction	
of	30%–36%	(Figure	3d–f).	Further,	AREG	depletion	in	stromal	cells	
affected	resistance	of	PCa	cells	to	cytotoxic	agents	such	as	MIT,	a	
capacity	conferred	by	the	full	spectrum	of	SASP	developed	in	PSC27	
(Figure	S3k).
Recently,	we	 disclosed	 the	 remarkable	 potential	 of	 a	 damaged	
TME	in	conferring	resistance	to	cancer	cells	that	survive	anticancer	
therapies,	 as	 exemplified	 by	 the	 SASP	 factors	 including	WNT16B	
and	SFRP2	(Sun	et	al.,	2012,	2016).	However,	whether	AREG	plays	
a role pathologically comparable to these factors in treatment‐dam‐
aged	TME	remains	unknown.	To	confirm	AREG	as	a	critical	effector	
of	the	SASP,	we	applied	cetuximab,	a	Food	and	Drug	Administration	
(FDA)‐approved	 EGFR‐targeting	 monoclonal	 antibody,	 to	 treat	
PCa	cells	alongside	 the	CM	of	PSC27‐BLEO.	We	 found	cetuximab	
F I G U R E  2  AREG	is	expressed	in	human	prostate	stroma	after	chemotherapy	and	correlated	with	adverse	clinical	outcome.	(a)	
Representative	images	of	AREG	expression	in	biospecimens	of	human	prostate	cancer	(PCa)	patients	after	histological	examination.	Left,	
immunohistochemical	(IHC)	staining.	Right,	hematoxylin	and	eosin	(HE)	staining.	In	each	staining	set,	top	tissues,	untreated;	bottom	tissues,	
treated.	Rectangular	regions	selected	in	the	left	images	per	staining	zoomed	on	the	right,	with	all	samples	acquired	from	the	same	patient.	
Scale bars = 200 μm.	(b)	Pathological	assessment	of	stromal	AREG	expression	in	PCa	samples	(untreated,	42	patients;	treated,	48	patients).	
Patients	were	pathologically	assigned	into	four	categories	per	IHC	staining	intensity	of	AREG	in	the	stroma.	(1)	negative;	(2)	weak;	(3)	
moderate;	and	(4)	strong	expression.	Left,	statistical	comparison	of	the	percentage	of	each	category.	Right,	representative	images	of	each	
category	regarding	AREG	signals.	EL,	expression	level.	Scale	bars	=	100	µm.	(c)	Boxplot	summary	of	AREG	transcript	expression	by	qRT–PCR	
analysis	upon	laser	capture	microdissection	(LCM)	of	cells	from	tumor	and	stroma,	respectively.	Signals	normalized	to	the	lowest	value	in	
the	untreated	cancer	epithelium	group,	comparison	performed	between	untreated	(42	patients)	and	treated	(48)	samples	per	cell	lineage.	
(d)	Comparative	analysis	of	AREG	expression	at	transcription	level	between	stromal	cells	collected	before	and	after	chemotherapy.	Each	
dot	represents	an	individual	patient,	with	the	data	of	“before”	and	“after”	connected	to	allow	direct	assessment	of	AREG	induction	in	the	
same	individual	patient.	Samples	from	10	patients	were	selected	for	assays.	(e)	Comparative	analysis	of	AREG	expression	at	transcription	
level	in	cancer	epithelial	cells	collected	from	the	same	individual	patients	as	described	in	(d).	(f)	Pathological	correlation	between	AREG,	
IL‐8,	and	WNT16B	in	the	stroma	of	PCa	patients	after	chemotherapy.	Scores	were	from	the	assessment	of	molecule‐specific	IHC	staining,	
with	expression	levels	colored	to	reflect	low	(blue)	via	modest	(green)	and	fair	(yellow)	to	high	(purple)	signal	intensity.	Columns	represent	
individual	patients,	and	rows	represent	different	SASP	factors.	Totally,	48	patients	treated	by	chemotherapy	were	analyzed,	with	scores	
of	each	patient	averaged	from	three	independent	pathological	readings.	(g)	Representative	images	of	AREG,	IL‐8,	and	WNT16B	expression	
in	the	TME	upon	IHC	staining	of	biospecimens	from	48	post‐treatment	PCa	patients.	The	p16INK4a and p21CIP1 images are shown to allow 
an	overview	of	senescent	cells	arising	at	the	tumor	foci	post‐treatment.	CD68	was	stained	to	locate	human	macrophages	in	the	TME.	
Scale bars = 100 μm.	(h)	Statistical	correlation	between	AREG	and	IL‐8	scores	(Pearson's	analysis,	r	=	0.98,	p	<	.0001)	in	the	48	tumors	with	
matching	protein	expression	data.	(i)	Statistical	correlation	between	AREG	and	WNT16B	scores	(Pearson's	analysis,	r = .96, p	<	.0001)	in	
the	same	tumors	as	described	in	(h).	(j)	Kaplan–Meier	analysis	of	PCa	patients.	Disease‐free	survival	(DFS)	stratified	according	to	AREG	
expression	(low,	average	score	<2,	turquoise	line,	n	=	20;	high,	average	score	≥2,	purple	line,	n	=	28).	DFS	represents	the	length	(months)	
of	period	calculated	from	the	date	of	PCa	diagnosis	to	the	point	of	first‐time	disease	relapse.	Survival	curves	generated	according	to	
the	Kaplan–Meier	method,	with	p	value	calculated	using	a	log‐rank	(Mantel–Cox)	test.	Data	in	all	bar	plots	are	shown	as	mean	±	SD and 
representative	of	three	biological	replicates.	Red	arrows	indicate	stroma,	and	yellow	arrows	indicate	cancer	epithelium	(a,	b,	g).	p values were 
calculated	by	Student's	t	test	(c,	d,	e),	one‐way	ANOVA	(b),	and	log‐rank	test	(j)	(^p > .05; ***p < .001; and ****p	<	.0001).	HR,	hazard	ratio
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substantially	deprived	the	ability	of	damaged	PSC27‐derived	CM	in	
conferring	 resistance	on	PCa	cells,	with	an	efficacy	similar	 to	 that	
of	the	small	molecule	inhibitor	AG1478	(Figure	3g).	As	the	target	of	
both	cetuximab	and	AG1478	 is	EGFR,	a	 receptor	physically	 recog‐
nized	and	interacted	by	AREG,	it	remains	unclear	whether	pharma‐
ceutically	 targeting	 AREG	with	 a	 target‐specific	 antibody	 is	 more	
effective	 in	 minimizing	 the	 acquired	 resistance	 of	 cancer	 cells.	 A	
significantly	decreased	cellular	viability	of	PCa	cells	was	observed	
when	AREG	mAb	was	 supplemented	with	 PSC27‐BLEO	CM,	with	
the	effect	comparable	to	or	even	higher	than	that	of	either	AG1478	
or	cetuximab	(p	<	.01	for	most	lines;	Figure	3g).	Interestingly,	when	
AREG	mAb	and	 cetuximab	were	 co‐applied	 to	 cell	 culture,	 the	ef‐
fect	generally	resembled	that	of	AREG	mAb	alone	(Figure	3g),	sug‐
gesting	addition	of	cetuximab	to	AREG	mAb	did	not	provide	extra	
benefit.	Although	PSC27‐BLEO	CM	 increased	 the	 viability	 of	PC3	
cells	exposed	to	MIT	at	0.1	~	1.0	μM, a range of dose that was de‐
signed to resemble the serum concentrations of this clinical agent in 
cancer	patients,	antibody‐mediated	AREG	depletion	markedly	com‐
promised stroma‐conferred cancer resistance with a result close to 
the	 condition	when	AREG	mAb	was	 combined	with	 cetuximab,	 as	
evidenced	by	the	remarkable	shift	of	both	PCa	and	BCa	cell	survival	
curves	 (p	 <	 .01;	 Figure	 3h;	 Figure	 S3l).	 Together,	 our	 data	 consis‐
tently	suggested	that	either	controlling	EGFR	as	a	plasma	membrane	
receptor	on	recipient	cells	or	targeting	AREG	as	a	soluble	factor	from	
damaged stromal cells can significantly deprive cancer cells of ac‐
quired	resistance	to	chemotherapeutic	agents.
2.4 | AREG reprograms the transcriptomics of 
cancer cells and alters their phenotypes
Given	 the	 remarkable	 changes	 in	 cancer	 cell	 phenotypes	 caused	
by	 paracrine	 AREG,	 we	 next	 sought	 to	 dissect	 the	 influence	 of	
AREG	on	cancer	cell	expression	pattern.	We	first	chose	to	perform	
transcriptome‐wide	 sequencing	 (RNA‐Seq)	 to	 quantitate	 gene	 ex‐
pression changes and profile the transcriptomics after treatment 
of	 PCa	 cells	with	 stromal	 AREG.	 Bioinformatics	 analysis	 indicated	
that 1888 transcripts were upregulated or downregulated signifi‐
cantly	(≥2‐fold,	p	<	.05)	in	PC3	cells	by	paracrine	AREG	(Figure	4a),	
while	 the	 expression	 of	 838	 transcripts	was	 changed	 in	AREG‐af‐
fected	DU145	cells	(Figure	S4a).	Although	the	vast	majority	of	these	
transcripts	were	protein‐coding	(1,362	and	390	for	PC3	and	DU145,	
respectively),	there	were	also	molecules	that	fall	into	subcategories	
such	as	long	noncoding	RNAs	(lncRNAs),	microRNAs	(miRNAs),	mis‐
cellaneous	RNAs	(misc‐RNAs),	pseudogenes,	processed	transcripts,	
antisense	RNAs,	and	3	prime	overlapping	ncRNAs	(Figure	4b).
After	mapping	the	transcripts	to	a	gene	ontology	(GO)	database	
comprising	HPRD,	 Entrez	 Gene,	 and	UniProt	 accession	 identifiers	
(Keshava	 Prasad	 et	 al.,	 2009;	Maglott,	 Ostell,	 Pruitt,	 &	 Tatusova,	
2011;	 UniProt,	 2010),	 followed	 by	 the	 analysis	 of	 transcripts	 that	
filtered through a more stringent threshold of fourfold upregulation 
with	available	human	genome	annotations	in	PCa	cells	(603/680	and	
285/499	 for	 PC3	 and	 DU145,	 respectively),	 we	 found	 an	 overlap	
class	of	96	transcripts	(Figure	4c;	Table	S5	for	the	top	list),	although	
their individual expression fold change and hierarchical order in 
these	cell	lines	differ.	Of	note,	multiple	genes	hitherto	known	to	be	
associated with prostate cancer progression were observed in the 
top	list	of	upregulated	entities	including	but	not	limited	to	MYBL2,	
ESM1,	 PBK,	 and	 UBE2C	 in	 PC3,	 and	MMP1,	 CCL5,	 and	 STC1	 in	
DU145	 (Figure	 4d;	 Figure	 S4b).	 To	 gain	 further	 biological	 insights	
into	 the	 AREG‐induced	 expression	 tendency,	 we	 investigated	 the	
datasets with GO programs by focusing on the top 30 transcripts per 
line. Surprisingly, the biological processes led by these transcripts 
in	both	PC3	and	DU145	cells	were	remarkably	modified,	showing	a	
distinct	pattern	characterized	by	alterations	in	cell	communication,	
signal transduction, nucleic acid metabolism, cell cycle, and immune 
response	 (Figure	4e;	 Figure	 S4c).	 Interestingly,	when	mapping	 the	
F I G U R E  3  Stromal	AREG	significantly	modifies	phenotypes	of	prostate	cancer	cells.	(a)	Immunoblot	analysis	of	EGFR‐associated	
pathways	in	PC3	and	DU145	cells	treated	by	the	CM	from	PSC27	cells	transduced	with	the	empty	vector	or	AREG	construct,	or	alongside	
the	EGFR	inhibitor	AG1478	(6	μM).	Antibodies	of	p‐EGFR	(Y845),	p‐Akt	(S473),	p‐mTOR	(S2448),	p‐Erk	(T202/Y204),	and	p‐Stat3	(S727)	were	
applied	to	probe	the	individual	molecules.	Total	protein	per	molecule	and	GAPDH	were	used	as	loading	control.	(b)	Immunoprecipitation	
(IP)	followed	by	immunoblot	assay	of	EGFR	and	AREG	in	the	whole‐cell	lysates	of	PC3	treated	by	the	CM	of	PSC27Vector	and	PSC27AREG for 
3	days.	Antibodies	including	IgG,	anti‐EGFR,	and	anti‐AREG	were	used	for	IP,	with	EGFR	and	AREG	in	inputs	analyzed	simultaneously.	E,	
anti‐EGFR.	A,	anti‐AREG.	GAPDH,	loading	control.	(c)	PSC27	cells	were	transduced	with	constructs	encoding	scramble	or	AREG‐specific	
shRNAs	to	make	stable	lines.	Cells	were	then	treated	with	either	DMSO	or	BLEO	and	subjected	to	SA‐β‐Gal	assay.	Upper,	comparative	
statistics.	Lower,	representative	images	of	SA‐β‐Gal‐stained	cells.	(d)	PCa	cells	were	treated	with	the	CM	from	PSC27	sublines	for	3	days	
and	subject	to	cell	proliferation	assay.	Native	and	shRNA‐transduced	PSC27	cells	as	indicated	were	treated	by	BLEO,	with	the	CM	collected	
7	days	after	treatment,	and	used	for	PC3	culture.	Alternatively,	an	anti‐AREG	monoclonal	antibody	was	employed	to	neutralize	AREG	in	the	
CM	before	cancer	cell	phenotypic	assays	(as	a	control,	also	for	e	and	f).	(e)	Migration	assay	of	PCa	cells	seeded	within	transwells	in	6‐well	
plates,	with	cells	cultured	for	3	days	in	the	CM	from	PSC27	sublines	depicted	in	(d).	Bottom,	representative	images	of	PC3	cell	migration	
measured	via	wound	healing	assay	at	72	hr	after	cultured	with	individual	CM.	Scale	bars	=	100	μm.	(f)	Invasiveness	appraisal	of	PCa	cells	
across	the	transwell	membrane	upon	culture	with	the	CM	from	PSC27	sublines.	Bottom,	representative	images	of	PC3	cell	invasion	across	
the	transwell	measured	at	72	hr	after	cultured	with	individual	CM.	Scale	bars	=	20	μm.	(g)	Chemoresistance	assay	of	PCa	cells	cultured	
with	the	CM	from	PSC27	sublines	described	in	(d).	MIT	was	applied	at	the	concentration	of	IC50	value	predetermined	per	cell	line.	
AG1478	(6	μM),	cetuximab	(50	μg/ml),	or	AREG	mAb	(1	μg/ml)	was	applied	alongside	with	PSC27	CM.	(h)	Dose–response	curves	(nonlinear	
regression/curve	fit)	plotted	from	drug‐based	survival	assays	of	PC3	cells	cultured	with	the	CM	of	PSC27	native	or	damaged	by	bleomycin	
(PSC27‐BLEO),	and	concurrently	treated	by	a	wide	range	of	concentrations	of	MIT.	AG1478	(6	μM),	cetuximab	(50	μg/ml),	and/or	AREG	mAb	
(1	μg/ml)	were	applied	with	PSC27	CM.	Data	are	representative	of	three	independent	experiments,	with	three	technical	replicates	run	per	
cell‐based experiment. P	values	were	calculated	by	Student's	t	test	(c,	d,	e,	f,	g)	(^p > .05; *p < .05; **p < .01; ***p < .001; and ****p	<	.0001)
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site	of	expression	of	PC3	and	DU145	transcripts	with	a	fold	change	
≥2	(p	<	.05),	we	observed	prominent	expression	of	genes	linked	to	
human	endothelial	cells	(represented	by	the	HUVEC),	a	phenomenon	
accompanied by the systemic expression change in genes correlated 
with	 epithelial‐to‐mesenchymal	 transition	 (EMT),	 cancer	 stem	 cell	
(CSC),	 and	 angiogenesis	 (ANG)	 development	 (Figure	 4f,g;	 Figure	
S4d,e).	 Thus,	 in	 addition	 to	 the	profound	gene	expression	pattern	
change,	AREG	induced	a	striking	epithelial‐to‐endothelial	transition	
(hereby	 termed	EET),	 suggesting	a	 salient	 capacity	of	AREG	 in	 re‐
programming the transcriptomics of cancer cells in the context of 
treatment‐remodeled	TME.
As	 supporting	 evidence,	 immunoblots	 suggested	 modified	 ex‐
pression	of	 the	markers	 intimately	associated	with	EMT,	CSC,	and	
ANG,	including	E‐cadherin,	N‐cadherin,	vimentin,	ALDH1A1,	CD44,	
CD31,	 and	 CD34	 (Figure	 4h).	 Further,	 expression	 change	 of	 each	
molecule observed in cancer cells can be completely reset to their 
individual	baseline	upon	elimination	of	AREG	from	stromal	cells,	as	
exemplified	by	the	typical	EMT	markers	(Figure	S4f).
In	 line	with	the	expression	pattern	shaped	by	paracrine	AREG,	
we	noticed	emergence	of	robust	tubule‐like	structures	when	cancer	
cells	were	exposed	to	the	AREG+	stromal	cell	CM	on	a	specialized	
calcein‐incorporated basement membrane matrix, as revealed by 
either phase‐contrast or immunofluorescence microscopic imaging 
(Figure	 4i	 and	 Figure	 S4g).	 Statistical	 appraisal	 suggested	 signifi‐
cantly	enhanced	capacity	of	both	PC3	and	DU	145	cells	in	forming	
capillary	tube	networks	in	the	presence	of	stromal	AREG	(Figure	4j).
2.5 | Therapeutically targeting AREG promotes 
tumor regression and prevents chemoresistance 
in vivo
Given	 the	 effects	 of	 paracrine	 AREG	 on	 cancer	 cell	 properties	 in	
vitro,	we	next	interrogated	whether	stromal	AREG	causes	any	path‐
ological	consequences	in	vivo.	First,	we	built	tissue	recombinants	by	
admixing	PSC27	sublines	with	PC3	cells	at	a	preoptimized	ratio	of	
1:4	before	 subcutaneously	 injecting	 them	 to	 the	hind	 flank	of	 ex‐
perimental mice with nonobese diabetes and severe combined im‐
munodeficiency	(NOD/SCID).	Animals	were	measured	for	tumor	size	
at	the	end	of	an	8‐week	period.	Compared	with	tumors	comprising	
PC3	and	PSC27Vector,	xenografts	composed	of	PC3	and	PSC27AREG 
exhibited	significantly	enhanced	volume	 (92.8%,	p	<	 .0001;	Figure	
S5a).	Conversely,	knockdown	of	AREG	from	PSC27AREG cells prior to 
tumor implantation resulted in considerably reduced tumor volumes 
(39.5%	and	42.5%	for	shRNAAREG#1	and	shRNAAREG#2, respectively, 
p	<	.0001	for	both).
To	closely	mimic	clinical	conditions,	we	experimentally	designed	
a preclinical regimen that incorporates genotoxic therapeutics and/
or	AREG/EGFR	inhibitors	 (Figure	5a;	Figure	S5b).	Two	weeks	after	
implantation	when	stable	uptake	of	tumors	in	vivo	was	observed,	a	
single	dose	of	MIT	or	placebo	was	delivered	to	animals	at	the	first	
day	 of	 3rd,	 5th,	 and	 7th	 week	 until	 end	 of	 the	 8‐week	 regimen.	
Contrasting	 to	 placebo‐treated	 group,	 MIT	 administration	 caused	
remarkably	delayed	tumor	growth	regardless	of	stromal	production	
of	AREG,	validating	the	efficacy	of	MIT	as	a	cytotoxic	agent	(54.6%	
for	 tumors	 comprising	 PSC27Vector	 and	 36.4%	 for	 those	 carrying	
PSC27AREG, respectively, p	<	.001	for	both;	Figure	5b).	However,	we	
noticed	significantly	enhanced	expression	of	SASP	factors	including	
IL‐6,	IL‐8,	WNT16B,	SFRP2,	ANGPTL4,	and	MMPs,	accompanied	by	
the	appearance	of	senescence	markers	such	as	p16INK4a	and	SA‐β‐Gal 
in	 xenograft	 tissues	 comprising	 PC3/PSC27Vector cells, suggesting 
the	development	of	an	in	vivo	cellular	senescence	and	typical	SASP	
triggered	 by	 genotoxicity	 (Figure	 5c;	 Figure	 S5c,d).	 Interestingly,	
some	of	the	SASP	factors	such	as	IL‐6	and	MMP10,	together	with	the	
typical	 senescence	markers	 including	 p16INK4a, were co‐expressed 
in stromal and cancer epithelial cells, suggesting drug treatment in‐
duced	comprehensive	in	vivo	cellular	senescence,	although	the	SASP	
profile seemed to develop differently between stromal and cancer 
cells	(Figure	5c;	Figure	S5c).	Specifically,	IHC	staining	revealed	pro‐
nounced	AREG	induction	in	the	MIT‐treated	xenografts,	with	signals	
predominantly	arising	from	the	stroma	(Figure	5d).
F I G U R E  4  Paracrine	AREG	modifies	cancer	cell	transcriptomics	and	induces	phenotypic	reprogramming.	(a)	Heatmap	depicting	
differentially	expressed	human	transcripts	in	PC3	cells	after	a	3‐day	culture	with	AREG+	CM.	In	contrast	to	cancer	cells	cultured	with	
control	CM	(vector),	726	and	1,162	genes	were	upregulated	and	downregulated,	respectively,	in	those	treated	with	the	CM	from	AREG‐
expressing	PSC27	cells	(AREG).	(b)	Statistics	of	transcripts	differentially	expressed	(fold	change	either	≥2	or	≤0.5,	with	p	<	.05)	in	PC3	and	
DU145	cells	upon	AREG	stimulation,	and	classified	into	typical	categories	according	to	functional	annotations	mapped	by	Gencode	(V27).	
(c)	Venn	diagram	indicating	the	overlap	of	96	transcripts	upregulated	in	PC3	and	DU145	cells	upon	treatment	with	AREG‐containing	CM	
from	stromal	cells	(603/680	and	285/499	genes	with	unique	annotations	for	PC3	and	DU145,	respectively).	(d)	Heatmap	showing	the	top	
30	upregulated	transcripts	by	AREG	in	PC3	cells,	sorted	according	to	their	expression	fold	changes	in	these	cells.	(e)Pie	chart	displaying	
the	biological	processes	(BPs)	that	are	most	pronouncedly	associated	with	transcripts	upregulated	by	AREG,	as	revealed	by	GO	analysis	
of	the	top	transcripts	in	PC3	line.	(f)	Column	chart	depicting	the	expression	sites	of	726	transcripts	upregulated	in	PC3	cells	after	AREG	
stimulation,	with	percentage	and	log10	(P	value)	per	specific	site	indicated	on	the	left	and	right	Y‐axis,	respectively.	Data	derived	from	by	
the	FunRich	program.	Red	star,	human	umbilical	vein	endothelial	cell	(HUVEC).	(g)	Heatmap	of	gene	expression	signatures	associated	with	
phenotypic	changes	including	epithelial‐to‐mesenchymal	transition	(EMT)/cancer	stem	cell	(CSC)/angiogenesis	(ANG)	after	AREG	stimulation	
of	PC3	cells.	Data	were	acquired	from	qRT–PCR	assays.	(h)	Immunoblot	assessment	of	protein‐level	expression	of	phenotype‐associated	
markers	displayed	in	(g).	GAPDH,	loading	control.	(i)	Representative	immunofluorescence	images	for	morphological	changes	observed	
in	PC3	and	DU145	cells,	upon	in	vitro	culture	for	3	days	with	AREG‐containing	CM	from	PSC27	cells.	PCa	cells	were	then	placed	on	the	
top	of	polymerized	Matrigel	in	12‐well	plates	for	10	hr,	and	tubular	structures	were	photographed	with	fluorescence	microscopy.	Scale	
bars = 100 μm.	(j)	Statistics	of	tube	formation	observed	for	PCa	cells	upon	treatment	as	described	in	(i).	Data	are	shown	as	the	percentage	
of	high‐power	fields	(HPFs).	Data	of	g–j	are	representative	of	three	independent	experiments,	with	three	technical	replicates	performed	per	
cell‐based	assay	(*p < .05 and ***p	<	.001)
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Next,	we	asked	whether	therapeutically	eliminating	AREG	from	
the	 full	SASP	spectrum	of	damaged	stoma	would	 further	enhance	
the	 therapeutic	 response	of	 tumors.	To	 this	end,	either	cetuximab	
or	AREG	mAb	was	administered	alongside	MIT	since	the	first	dose	
of	preclinical	administration.	Although	MIT	treatment	caused	promi‐
nent	shrinkage	of	tumors	composed	of	PC3	cells	thoroughly	(40.5%),	
administration of therapeutic antibodies did not show any effect 
(p	 >	 .05;	 Figure	 5e).	 Interestingly,	 the	 antibodies	 did	 not	 provide	
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further	benefits	even	when	used	together	with	MIT,	 implying	that	
PC3	tumors	grow	in	a	 largely	EGF/EGFR	axis‐independent	manner	
in	 the	absence	of	 surrounding	 stromal	 cells.	Upon	 implantation	of	
PC3	cells	together	with	their	stromal	counterparts,	tumor	volumes	
significantly	increased	(170.1%,	p	<	.001;	Figure	5e),	substantiating	
the tumor‐promoting effect of stromal cells in vivo. However, when 
animals	carrying	PC3/PSC27	tumors	were	treated	with	MIT,	tumor	
volumes	 decreased	 significantly	 (34.3%,	p	 <	 .001).	Of	 note,	when	
either	 cetuximab	 or	AREG	mAb	was	 co‐administered	with	MIT	 as	
dual	agents,	tumor	showed	further	reduction	in	end	volume	(37.8%	
and	46.8%,	respectively;	Figure	5e).	Alternatively,	bioluminescence	
imaging	 (BLI)	 of	 xenografts	 generated	with	 cancer	 cells	 stably	 ex‐
pressing	luciferase	(PC3‐luc)	and	stromal	cells	excluded	the	potential	
metastasis of cancer cells from the primary sites, with signals essen‐
tially	supporting	tumor	growth	patterns	we	observed	in	PC3/PSC27	
animals	 (Figure	 5f).	 The	 data	 suggest	 that	 classic	 chemotherapy	
combined	with	a	TME‐targeting	agent	can	induce	tumor	responses	
more dramatically than chemotherapy alone, and the efficacy of an 
AREG‐specific	monoclonal	antibody	is	even	superior	to	cetuximab,	
an	 anti‐EGFR	 antibody	widely	 applied	 to	 restrain	 EGFR+ neoplas‐
tic cell expansion by promoting their apoptosis in clinical patients 
(Mancini	et	al.,	2017).
To	investigate	the	mechanism	directly	responsible	for	AREG‐in‐
duced cancer resistance, we dissected tumors from animals treated 
by different agents 7 days after treatment, a time point prior to the 
development	of	resistant	colonies.	 In	contrast	to	the	placebo,	MIT	
administration	 caused	 dramatically	 increased	 DNA	 damage	 and	
apoptosis.	 Although	 cetuximab	 alone	 did	 not	 induce	 typical	DDR,	
PC3	tumors	displayed	enhanced	cell	death,	presumably	due	to	the	
competent	binding	affinity	of	 cetuximab	 to	EGFR,	a	property	 that	
minimizes	cancer	survival	(Figure	5g).	However,	when	combined	with	
MIT,	cetuximab	did	not	exhibit	prominent	efficacy	in	enhancing	cell	
apoptosis, implying a reduced cytotoxicity when administered with 
MIT	in	these	animals.	In	contrast	to	cetuximab,	however,	AREG	mAb	
generated significantly, albeit slightly more apoptotic cells in tumor 
xenografts	(Figure	5g).	There	was	elevated	caspase	3	cleavage,	a	typ‐
ical	hallmark	of	cell	apoptosis,	when	AREG	mAb	was	administered	
(Figure	5h).	Of	note,	MIT‐mediated	chemotherapy	enhanced	circu‐
lating	 AREG	 level	 in	 the	 plasma,	 which	was	 substantially	 reduced	
when	AREG	mAb	was	used	as	a	therapeutic	antibody	(Figure	5i).	We	
further	assessed	the	expression	of	angiogenesis‐associated	markers	
including	CD31	and	CD34	in	LCM‐isolated	cancer	cells	from	tumor	
xenografts, and found both factors significantly upregulated when 
animals	were	subject	to	chemotherapy	(Figure	S5e).	However,	upon	
combination	of	MIT	treatment	with	AREG	mAb	administration,	up‐
regulation	of	CD31	and	CD34	was	substantial	reversed,	implying	an	
angiogenesis‐promoting	capacity	of	AREG	under	these	in	vivo	con‐
ditions.	The	competency	of	AREG	mAb‐caused	reversion	of	chemo‐
therapy‐elicited changes in cancer cells was further supported by 
similar	 changes	 in	 several	 EMT‐specific	markers	 (Figure	 S5e),	 data	
consistent with our findings from cancer cell‐based in vitro assays 
(Figure	4g,h;	Figure	S4e,f).
2.6 | Stromal AREG induces PD‐L1 expression in 
tumors and is an optimal TME target to enhance 
immunotherapeutic index
The	efficacy	of	conventional	anticancer	drugs	not	only	involves	direct	
cytotoxic/cytostatic	effects,	but	also	relies	on	the	(re)activation	of	
tumor‐targeting	immune	activities	(Galluzzi,	Buque,	Kepp,	Zitvogel,	
&	 Kroemer,	 2015).	 We	 thus	 asked	 whether	 the	 treatment‐dam‐
aged	TME	alters	the	response	of	cancer	cells	to	immunotherapeutic	
agents.	Our	expression	database	suggested	that	PD‐L1	(also	CD274,	
B7‐H1)	 was	 substantially	 upregulated	 in	 PCa	 cells	 after	 exposure	
to	PSC27AREG	CM	(Table	S5),	consistent	with	the	pathological	data	
which	demonstrated	remarkable	expression	of	PD‐L1	in	primary	tis‐
sues	of	post‐treatment	PCa	patients	(Figure	6a).	Expression	level	of	
PD‐L1	in	tumor	foci	is	significantly	correlated	with	poor	disease‐free	
survival	in	post‐treatment	period	(p	<	.01,	log‐rank	test;	Figure	6b).	
We	 further	 noticed	 a	prominent	 linear	 correlation	between	AREG	
F I G U R E  5  Therapeutically	targeting	AREG	in	the	damaged	TME	promotes	tumor	responses.	(a)	Experimental	diagram	for	nonobese	
diabetes	and	severe	combined	immunodeficient	(NOD/SCID)	mice.	Two	weeks	after	subcutaneous	implantation	and	in	vivo	uptake	of	tissue	
recombinants,	animals	received	either	single	(mono)	or	combinational	(dual)	agents	administered	as	metronomic	treatments	composed	of	
several	cycles.	(b)	Statistical	profiling	of	tumor	end	volumes.	PC3	cells	were	xenografted	alone	or	together	with	PSC27	cells	to	the	hind	
flank	of	NOD/SCID	mice.	Prior	to	implantation,	PSC27	cells	were	transduced	with	the	control	vector	or	AREG	construct	to	make	stable	
sublines.	The	chemotherapeutic	drug	MIT	was	administered	to	induce	tumor	regression.	(c)	Transcript	assessment	of	several	canonical	
SASP	factors	expressed	in	stromal	cells	isolated	from	the	tumors	of	NOD/SCID	mice.	Tissues	from	animals	implanted	with	both	stromal	and	
cancer	cells	in	tumor	grafts	were	subject	to	LCM	isolation,	total	RNA	preparation,	and	expression	assays.	(d)	Representative	IHC	images	
of	AREG	expression	in	tissues	isolated	from	placebo‐	or	MIT‐treated	animals.	Square	regions	in	the	upper	images	were	zoomed	into	lower	
images. Red arrows indicate stroma, and yellow arrows indicate cancer epithelium. Scale bars = 50 μm.	(e)	Statistical	comparison	of	tumor	
growth	in	animals	that	underwent	several	different	treatment	modalities.	Mice	received	PC3	cells	implanted	alone	or	combined	with	PSC27	
cells	before	treatment	by	the	chemotherapeutic	drug	(MIT)	or	combinational	agents	(MIT/cetuximab	or	MIT/AREG	mAb).	Tumor	volumes	
were	measured	at	the	end	of	an	8‐week	preclinical	regimen.	(f)	Representative	bioluminescence	imaging	(BLI)	of	PC3/PSC27	tumor‐bearing	
animals	in	the	preclinical	trial.	Digital	signals	were	proportional	to	in	vivo	luciferase	activities	measured	by	an	IVIS	device.	(g)	Statistical	
assessment	of	DNA‐damaged	and	apoptotic	cells	in	the	biospecimens	analyzed	in	(e).	Values	are	presented	as	percentage	of	cells	positively	
stained	by	IHC	with	antibodies	against	γ‐H2AX	or	caspase	3	(cleaved).	(h)	Representative	IHC	images	of	caspase	3	(cleaved)	in	tumors	at	the	
end	of	therapeutic	regimes.	Biopsies	of	placebo‐treated	animals	served	as	negative	controls	for	MIT‐treated	mice.	Scale	bars	=	100	μm.	(i)	
Serum	AREG	concentration	assessment	of	experimental	mice	treated	by	chemotherapy	and/or	AREG	mAb.	Data	were	derived	from	human	
AREG‐specific	ELISAs.	Data	are	representative	of	three	independent	experiments.	P	values	were	calculated	by	Student's	t	test	(b,	c,	e,	g,	i)	
(^p > .05; *p < .05; **p < .01; ***p < .001; and ****p	<	.0001)
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expression	in	the	stroma	and	PD‐L1	expression	in	the	primary	tumor	
(p	<	.0001;	Figure	6c).
Although	PD‐L1	is	subject	to	induction	by	AREG,	PD‐L2	and	PD‐1	
remain largely unchanged, a fact supported by the data from both 
RNA‐Seq	 and	 qRT–PCR	 (Figure	 6d;	 Figure	 S6a).	 The	 findings	 were	
largely reproduced by immunoblot assay of these molecules in cancer 
cells	(Figure	S6b).	Further,	we	noticed	that	expression	level	of	PD‐1,	
the receptor expressed on plasma membrane of immune cells including 
cytotoxic	T	lymphocytes	(CTLs)	and	specifically	interacted	by	PD‐L1/
PD‐L2,	remained	unchanged	in	human	peripheral	blood	mononuclear	
cells	(PBMCs)	upon	exposure	to	AREG+	stromal	CM	(Figure	S6b).
EGFR‐mediated	Akt	activation	is	associated	with	PD‐L1	expres‐
sion,	which	can	be	 reduced	by	EGFR	 inhibitors	 in	cancer	cell	 lines	
carrying	 activated	 EGFR	 (Akbay	 et	 al.,	 2013).	We	 asked	 whether	
PD‐L1	 upregulation	 by	 paracrine	 AREG	 is	 subject	 to	 intracellular	
signaling	that	involves	EGFR,	its	downstream	factors,	or	other	mole‐
cules	in	recipient	cancer	cells.	To	address	this,	a	group	of	small	mol‐
ecule	inhibitors	including	those	targeting	EGFR	(erlotinib,	AG1478),	
PI3K	 (LY294002),	 Akt	 (MK2206),	 mTOR	 (rapamycin),	 Mek1/2	
(PD0325901),	 NF‐κB	 (Bay	 11–7082),	 Jak1/2	 (ruxolitinib),	 and	 p38	
(SB203580)	was	individually	applied	to	treat	PCa	cells	together	with	
stromal	AREG.	Interestingly,	almost	all	of	these	inhibitors	markedly	
dampened	 PD‐L1	 production	 even	 in	 the	 presence	 of	 paracrine	
AREG,	although	suppression	of	p38	failed	to	cause	PD‐L1	reduction	
(Figure	S6c).	Together,	our	data	evidently	showed	the	regulation	of	
AREG‐induced	PD‐L1	synthesis	in	PCa	cells,	a	process	that	function‐
ally	 involves	EGFR	and	 its	downstream	elements	 including	but	not	
limited	to	PI3K,	Akt,	mTOR,	Mek1/2,	Jak1/2,	and	NF‐κB,	while	p38,	
one of the major cellular stress sensors, did not seem to be engaged.
Next,	 we	 investigated	 the	 influence	 of	 AREG‐induced	 PD‐L1	
expression	on	 the	 immune	 activity	 of	 human	CTLs	 against	 cancer	
cells,	 by	employing	PBMCs	 freshly	 collected	 from	human	patients	
and	monitoring	their	efficacy	in	targeting	PCa	cells.	In	the	presence	
of	stromal	AREG,	survival	of	cancer	cells	was	remarkably	enhanced	
even	when	PBMCs	were	added	to	culture.	However,	the	advantage	
was	minimized	upon	PD‐L1	elimination	 from	PCa	 cells	 (Figure	6e;	
Figure	S6d,e).	We	further	observed	elevated	survival	of	cancer	cells	
when	 they	were	 exposed	 to	 the	CM	 from	PSC27	 predamaged	 by	
BLEO,	 which	 was	 reversed	 upon	 PD‐L1	 depletion	 in	 cancer	 cells	
(Figure	6f;	Figure	S6f).	Of	note,	PCa	cell	 survival	decreased	when	
AREG	was	 eliminated	 from	 PSC27,	 although	 the	 reduction	 extent	
in	 the	 presence	 of	 activated	 PBMCs	was	 slightly	 but	 significantly	
less	than	that	caused	by	PD‐L1	depletion	from	PCa	cells	(Figure	6f;	
Figure	S6f).	The	data	strongly	suggest	that	stromal	AREG‐mediated	
PD‐L1	expression	in	cancer	cells	represents	a	major	force	of	resis‐
tance to immunosurveillance, a response triggered by the damaged 
stroma but indeed exploitable to enhance the sensitivity of tumors 
to immunotherapeutic agents.
We	 next	 explored	 the	 feasibility	 and	 efficacy	 of	 tumor	 treat‐
ment	 by	 combining	 chemotherapy	 and	 immunotherapy.	 Previous	
studies demonstrated that human lymphocytes transferred into 
immunodeficient mice can undergo activation and redistribution to 
murine organs, while administration of therapeutic antibodies in‐
cluding	nivolumab	is	able	to	restrain	tumor	progression	(Sanmamed	
et	al.,	2015).	We	hereby	chose	to	use	Rag2−/−IL2Rγnull mice, which 
are	devoid	of	T,	B,	and	NK	lymphocytes	and	permit	to	establish	hu‐
manized	animal	models	(Herndler‐Brandstetter	et	al.,	2017).	Human	
PBMCs	 were	 intravenously	 transplanted	 before	 establishment	
F I G U R E  6  Stromal	AREG	induces	PD‐L1	expression	in	tumors	and	is	an	exploitable	target	to	enhance	immunotherapeutic	sensitivity.	
(a)	Pathological	assessment	of	primary	tumors	of	PCa	patients	before	and	after	chemotherapy.	Left,	IHC	image	of	PD‐L1	staining.	Right,	
HE	staining.	Top,	untreated.	Bottom,	chemo‐treated.	Red	arrows	indicate	stroma,	and	yellow	arrows	indicate	cancer	epithelium.	Scale	
bars = 100 μm.	(b)	Kaplan–Meier	profiling	of	PCa	patient	survival.	Disease‐free	survival	(DFS)	stratified	according	to	PD‐L1	expression	(low,	
average score <2, blue line, n	=	23;	high,	average	score	≥2,	yellow,	n	=	25).	DFS	represents	the	length	(months)	of	period	calculated	from	
the	date	of	PCa	diagnosis	to	the	point	of	first‐time	disease	relapse.	Survival	curves	generated	according	to	the	Kaplan–Meier	method,	with	
P	value	calculated	using	a	log‐rank	(Mantel–Cox)	test.	(c)	Statistical	correlation	between	AREG	and	PD‐L1	pathological	scores	(Pearson's	
analysis, r = .96, p	<	.0001)	in	the	48	tumors	with	matching	protein	expression	data.	(d)	Comparative	analysis	of	PD‐L1/PD‐L2/PD‐1	
expression	in	PC3	cells	cultured	with	CM	of	control	(vector)	or	AREG‐overexpressing	(AREG)	PSC27	cells.	Top,	expression	profile	generated	
from	RNA‐Seq	data.	Bottom,	qRT–PCR	analysis	of	above	gene	expression	in	PC3	cells.	(e)	Survival	evaluation	of	PC3	cells	upon	3‐day	
culture	with	either	control	(vector)	or	AREG‐containing	(AREG)	CM	of	PSC27	cells,	in	the	presence	of	human	peripheral	blood	mononuclear	
cells	(PBMCs).	PC3	cells	were	lentivirally	infected	with	scramble	(C)	or	PD‐L1‐specific	shRNAs	(#2,	#3)	to	make	sublines	prior	to	in	vitro	
treatment.	(f)	PC3	sublines	described	above	were	subject	to	culture	with	CM	of	treatment‐naive	(CTRL)	or	bleomycin‐damaged	(BLEO)	
PSC27	cells,	while	human	PBMCs	were	applied.	Results	were	evaluated	as	the	percentage	of	PC3	cells	that	survived	3	days	of	continuous	
culture.	PC3	cells	lentivirally	infected	with	AREG‐specific	shRNAs	(#1,	#2)	were	examined	as	parallel	controls.	(g)	Illustrative	diagram	of	
the	preclinical	trial	involving	a	humanized	mouse	model.	To	assess	the	anticancer	properties	of	immune‐stimulatory	monoclonal	antibodies	
(atezolizumab,	anti‐PD‐L1;	nivolumab,	anti‐PD‐1;	and	AREG	mAg,	anti‐AREG),	Rag2−/−IL2Rγnull	mice	with	T,	B,	and	NK	lymphocyte	deficiency	
were	intravenously	(i.v.)	injected	with	7	×	106	human	PBMCs	3	days	before	subcutaneous	(s.c.)	implantation	of	1.2	×	106	PC3	cells	with	
or	without	0.3	×	106	PSC27	cells	to	the	hind	flank.	Two	weeks	after	tumor	xenografting,	therapeutic	antibodies	(i.v.)	were	provided	alone	
or	together	with	MIT	(i.p),	with	the	treatment	performed	once	every	other	week	for	three	cycles.	At	the	end	of	the	8‐week	regimen,	
animals	were	sacrificed,	with	tumors	collected	for	pathological	appraisal.	(h)	Statistical	comparison	of	end	volumes	of	tumors	grown	in	
Rag2−/−IL2Rγnull	animals	that	experienced	different	treatment	modalities	as	described	above.	Mice	received	PC3	cells	implanted	alone	were	
assessed	as	counterpart	control	to	those	xenografted	with	PC3/PSC27	recombinants.	Tumor	volumes	were	measured	at	the	end	of	the	8‐
week	preclinical	regimen.	(i)	Pathological	analysis	of	humanized	animals.	Top,	IHC	images	derived	from	IHC	staining	against	PD‐L1.	Bottom,	
HE	images.	Tumor	tissues	from	placebo‐,	MIT‐,	MIT/atezolizumab‐,	and	MIT/AREG	mAb‐treated	mice	are	displayed	as	exemplifying	samples.	
Data are representative of three independent experiments. p	values	were	calculated	by	Student's	t	test	(e,	f,	h)	(^p > .05; *p < .05; **p < .01; 
***p < .001; and ****p	<	.0001)
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of	 subcutaneous	 tumor	 xenografts.	 Atezolizumab	 or	 nivolumab,	
each	 an	 FDA‐approved	 monoclonal	 anti‐PD‐L1/PL1	 agent,	 was	
administered to Rag2−/−IL2Rγnull	 mice	 after	 PC3/PSC27	 implanta‐
tion	 (Figure	6g).	As	a	hallmark	of	activated	CTLs	 is	the	production	
of	 cytokines,	we	examined	animal	plasma	and	observed	 increased	
human interferon‐γ	 (h‐IFN‐γ)	 and	 TNF‐α	 (h‐TNF‐α)	 levels	 in	 mice	
that	received	atezolizumab	or	nivolumab,	but	not	MIT,	control	IgGs,	
or	AREG	mAb	(Figure	S6g,h).	The	data	suggest	that	the	PD‐L1/PD‐1	
agents	effectively	activated	transplanted	PBMCs	and	induced	sub‐
stantial	production	of	typical	cytokines	in	vivo.
Preclinical	 results	 indicated	 that	MIT	 significantly	 reduced	 the	
volumes	of	tumors	composed	of	PC3	cells	only,	with	an	extent	more	
dramatic	 than	 atezolizumab	 or	 nivolumab	 (Figure	 S7a).	 Although	
AREG	 mAb	 failed	 to	 generate	 any	 remarkable	 changes	 to	 tumor	
growth,	combination	of	this	antibody	with	MIT	achieved	prominent	
effects in abrogating tumor progression, with the efficiency ap‐
proaching	that	manifested	by	combined	use	of	MIT	with	a	PD‐L1/
PD‐1‐targeting	antibody.
We	next	 focused	on	the	consequence	of	chemotherapy	and/
or immunotherapy on the development of tumors comprising can‐
cer	cells	and	their	stromal	counterparts.	Contrasting	to	PC3	alone,	
co‐implantation	of	PC3	and	PSC27	cells	led	to	significantly	higher	
tumor	volume,	consistent	with	the	results	we	observed	 in	NOD/
SCID	animals	(Figure	6h).	Although	administration	of	either	atezoli‐
zumab	or	nivolumab	alone	remarkably	decreased	tumor	sizes,	they	
were	less	effective	than	MIT	treatment,	suggesting	the	limited	ef‐
ficacy	of	targeting	PD‐L1/PD‐1	in	these	animals.	Of	note,	the	re‐
duction	extent	of	tumor	volumes	achieved	by	MIT/AREG	mAb	was	
slightly	 but	 significantly	 higher	 than	 that	 caused	 by	 either	MIT/
atezolizumab	or	MIT/nivolumab,	not	only	underscoring	the	supe‐
rior	potential	of	classic	chemotherapy	combined	with	anti‐PD‐L1/
PD‐1	agents	in	functionally	competent	TME,	but	also	proving	that	
the	modality	can	be	alternatively	reconstituted	by	replacing	PD‐
L1/PD‐1	antibodies	with	 an	AREG	mAb	 (Figure	6h).	After	 tumor	
histological	dissection,	we	further	found	that	delivery	of	MIT	in‐
duced	substantial	expression	of	PD‐L1	in	the	tumor	foci,	a	process	
markedly	counteracted	when	MIT	was	co‐administered	with	AREG	
mAb	but	not	a	PD‐L1/PD‐1‐targeting	agent	such	as	atezolizumab	
(Figure	6i).
To	validate	the	findings	in	a	hormone‐native	setting,	we	gener‐
ated	 tumor	 xenografts	with	VCaP,	 a	 prostate	 cancer	 cell	 line	 that	
expresses	androgen	receptor	(AR)	and	grows	in	an	androgen‐sensi‐
tive	manner	(Kim,	Watson,	et	al.,	2018).	Combination	of	VCaP	and	
PSC27	presented	 results	 similar	 to	 those	observed	 in	PC3/PSC27	
tumors	 (Figure	 S7b),	 suggesting	 that	 the	 efficacy	 of	 therapeutic	
agents	 is	essentially	hormone‐independent.	To	further	expand,	we	
performed	studies	with	human	breast	cancer	(BCa)	xenografts	con‐
sisting	of	MDA‐MB‐231,	a	malignant	BCa	cell	line,	and	HBF1203,	a	
breast	stromal	line.	Preclinical	assays	showed	that	BCa	data	largely	
reproduced	those	obtained	from	PCa	trials	(Figure	S7c).
To	validate	the	safety	and	feasibility	of	the	therapeutic	regimens,	
we performed pathophysiological assays. Our data suggested that 
either single or combinational treatment was well tolerated, with 
mice maintaining normal body weight throughout the therapeutic 
regimen	(Figure	S7d).	Together,	these	results	suggest	that	combining	
conventional	chemotherapy	with	an	AREG‐	or	PD‐L1/PD‐1‐target‐
ing agent has the competency to enhance tumor response without 
causing severe in vivo cytotoxicity.
2.7 | AREG is a novel biomarker imaging in vivo 
SASP and implies potential immunosuppression in a 
treatment‐damaged TME
We	next	sought	to	assess	whether	AREG	is	experimentally	detect‐
able	in	the	circulating	system	of	cancer	patients	post‐treatment.	To	
this	end,	we	collected	peripheral	blood	from	PCa	patients,	including	
one cohort that experienced chemotherapy and the other that did 
not.	Upon	serum	analysis	of	chemo‐treated	patients	by	antigen‐spe‐
cific	ELISA,	we	found	AREG	plasma	level	in	the	treated	cohort	sig‐
nificantly	higher	than	that	of	the	treatment‐naïve	group	(Figure	7a).	
Notably,	the	tendency	was	phenocopied	by	IL‐8,	a	canonical	hallmark	
factor	of	the	SASP	(Figure	7b).	The	data	suggested	development	of	
an	in	vivo	SASP,	the	index	of	which	can	be	technically	measured	by	
quantifying	the	concomitantly	expressed	SASP	factors	including	but	
not	 limited	to	AREG	and	IL‐8	in	the	peripheral	blood	of	post‐treat‐
ment cancer patients.
We	 interrogated	 whether	 the	 amount	 of	 circulating	 AREG	 is	
indeed	 correlated	with	 that	 of	 other	 typical	 SASP	 factors	 such	 as	
IL‐8	 in	 a	 same	 individual	 patient	 after	 treatment.	Upon	evaluation	
by	ELISA,	we	noticed	a	significant	and	positive	correlation	between	
AREG	and	IL‐8	(Figure	7c).	Further,	immunoblots	not	only	confirmed	
enhanced	AREG	and	IL‐8	levels	in	the	serum	of	chemo‐treated	PCa	
patients rather than those untreated, but also displayed simultane‐
ously occurring changes in these two factors, thus validating their 
correlation	at	serum	level	(Figure	7d).	Additional	datasets	were	ob‐
tained	from	the	cohorts	of	BCa,	an	alternative	solid	tumor	type,	thus	
providing	an	extra	set	of	evidence	supporting	increased	AREG/IL‐8	
expression and their significant correlation in the peripheral system 
of	post‐treatment	populations	(Figure	S8a–c).
To	gain	further	insights,	we	performed	longitudinal	investigation	
in the primary tumor tissue and circulating blood of the post‐treat‐
ment	cohort	(20	patients).	Strikingly,	cross‐organ	analysis	indicated	
a	remarkable	association	between	the	tissue	expression	and	serum	
level	of	each	factor,	with	the	amounts	of	AREG	and	IL‐8	seemingly	
in	 parallel	 for	 each	 individual	 patient	 (Figure	 7e).	 To	 establish	 the	
appropriateness	and	 reliability	of	employing	AREG/IL‐8	 for	 in	vivo	
SASP	measurement,	we	selectively	acquired	stromal	cells	from	the	
primary	tissues	of	PCa	patients	via	LCM,	and	analyzed	the	expres‐
sion	of	a	subset	of	signature	SASP	factors,	including	but	not	limited	
to	MMP1,	CXCL3,	IL‐1β,	WNT16B,	IL‐6,	and	GM‐CSF	(Figure	S8d).	
Interestingly, expression of the vast majority of these factors in 
stroma	consistently	paralleled	the	alteration	of	both	AREG	and	IL‐8	
in	the	same	tissue,	with	patient	samples	organized	from	low	to	high	
per	factor	fold	change.	However,	not	surprisingly,	several	non‐SASP	
factors	such	as	IL‐2/3/5/12/17	failed	to	show	such	a	distinct	correla‐
tion	(Figure	S8d).	Thus,	our	data	suggest	that	AREG	represents	one	
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of	the	major	TME‐derived	soluble	factors	and	precisely	reflects	the	
development	of	an	in	vivo	SASP,	and	thus	can	be	exploited	to	assess	
the	magnitude	of	the	SASP	in	cancer	patients	after	clinical	therapy.	
Further,	we	observed	a	significant	and	negative	correlation	between	
AREG	serum	 index	and	patient	survival	 in	 the	post‐treatment	PCa	
cohort,	 which	 resembled	 the	 data	 from	 the	 post‐treatment	 BCa	
patients	 (Figure	 7f;	 Figure	 S8e).	 Similar	 to	 the	 PCa	 clinical	 data	
(Figure	6c),	expression	 level	of	AREG	in	BCa	stroma	appears	to	be	
intimately	correlated	with	that	of	PD‐L1	in	their	adjacent	tumor	foci	
(Figure	S8f),	further	substantiating	the	potential	of	AREG	to	be	ex‐
ploited	as	a	molecular	indicator	for	immune	checkpoint	activation	in	
a	functionally	active	TME.	Although	AREG	is	subject	to	frequent	mu‐
tation, amplification, deep deletion, and even multiple alternations in 
cancer	patients	as	revealed	by	the	TCGA	genomics	data	(Figure	7g),	
routine	surveillance	of	AREG	through	a	noninvasive	strategy	such	as	
liquid	biopsy	provides	a	novel,	precise,	and	straightforward	avenue	
for both treatment efficacy assessment and prognosis of advanced 
malignancies in future clinical oncology.
3  | DISCUSSION
Resistance to anticancer treatments is a major problem in both can‐
cer	 research	 and	 clinical	 practice.	 The	 mechanisms	 of	 resistance	
to “classic” cytotoxic chemotherapy, radiation, and even targeted 
therapy share several features, including modifications of the drug 
target, activation of pro‐survival pathways, and disability of apop‐
tosis	 machineries	 (Holohan,	 Schaeybroeck,	 Longley,	 &	 Johnston,	
2013).	With	the	mounting	arsenal	of	anticancer	agents	and	the	ad‐
vancement	of	high‐throughput	screening	techniques,	there	are	now	
unprecedented	opportunities	to	tackle	cancer	resistance	via	clinical	
assessment of rational therapeutic drug combinations and explora‐
tion	 of	 precise	 biomarkers	 to	 enable	 patient	 stratification.	 In	 this	
study,	we	uncovered	 that	AREG,	a	soluble	 factor	produced	by	 the	
treatment‐damaged	TME,	confers	pronounced	resistance	on	surviv‐
ing cancer cells and simultaneously creates an immunosuppressive 
microenvironment	by	engaging	PD‐L1,	a	type	I	transmembrane	pro‐
tein	that	functionally	activates	the	immune	checkpoint	(Figure	7h).	
Released	 as	 one	of	 the	 hallmark	 SASP	molecules,	AREG	 is	 readily	
detectable in the circulating system of post‐treatment cancer pa‐
tients	 and	 can	be	exploited	 as	 a	 novel	 and	noninvasive	biomarker	
for evaluation of therapeutic effects and clinical prognosis of patient 
outcome in cancer medicine.
Chemotherapy	 is	 one	 of	 the	 principal	 anticancer	 modalities.	
However,	much	like	other	type	of	treatments,	the	effectiveness	of	
chemotherapeutics is limited by drug resistance, which can be di‐
vided	into	two	broad	categories:	intrinsic	and	acquired.	In	contrast	
to intrinsic resistance, which re‐exists in cancer cells before initiation 
of	treatments,	acquired	resistance	arises	in	the	course	of	therapies	
and	is	frequently	supported	by	the	tumor‐adjacent	stroma	(Junttila	&	
de	Sauvage,	2013).	For	instance,	cancer	resistance	can	be	driven	by	a	
treatment‐damaged	TME,	which	is	pathologically	fueled	by	the	SASP	
(Sun	et	al.,	2012,	2016;	Zhang	et	al.,	2018).	Originally	discovered	as	
an	essential	biological	feature	of	senescent	cells,	the	SASP	is	now	es‐
tablished as an important contributor in the development of multiple 
aging‐related complications, including atherosclerosis, osteoarthri‐
tis,	physical	 frailty,	 and	 systemic	 inflammation	 (Childs	et	 al.,	2016;	
Demaria	et	al.,	2017;	Jeon	et	al.,	2017;	Zhu	et	al.,	2015).	However,	
increasing	lines	of	evidence	support	that	the	SASP	has	broad	impli‐
cations	in	human	cancers.	Although	highly	context‐dependent,	the	
SASP	serves	many	consistent	functions	in	the	TME,	including	those	
involved in cancer initiation, growth, metastasis, and even relapse 
(Demaria	et	al.,	2017).	In	contrast	to	studies	that	support	the	bene‐
ficial	effects	of	TIS	induction	in	cancer	cells,	including	tumor	growth	
stalling	 and	 the	 SASP‐mediated	 immune	 response	 that	 promotes	
elimination of senescent cancer cells, therapy‐triggered off‐target 
effects	on	the	surrounding	benign	TME	components	can	have	un‐
desirable outcome during and after cancer treatment, particularly 
when	cancer	cells	develop	acquired	 resistance	against	subsequent	
cycles of therapeutic intervention.
Synthesized	 as	 a	 membrane‐anchored	 precursor	 protein	 that	
can	engage	juxtacrine	signaling	on	adjacent	cells,	AREG	is	a	member	
of	the	EGF	family	(Berasain	&	Avila,	2014).	The	biological	effect	of	
AREG	is	mainly	mediated	through	its	binding	and	activation	of	EGFR	
(also	ErbB1),	 a	widely	expressed	 transmembrane	RTK	 (Avraham	&	
Yarden,	2011).	By	comparison	of	multiple	cell	 lines	and	anticancer	
treatments, we showed that stromal cells are more ready to express 
AREG	than	cancer	cells	upon	treatment	by	DDA	agents	that	cause	
typical	DNA	lesions,	instead	of	NDDA	treatments	that	do	not	target	
DNA,	a	feature	that	 is	 indeed	shared	by	most	of	the	SASP	factors	
(Zhang	et	al.,	2018).	Intriguingly,	AREG	can	be	alternatively	delivered	
via extracellular vesicles such as exosomes in the treatment‐naïve 
settings of multiple myeloma, non‐small‐cell lung cancer, and chronic 
myelogenous	 leukemia,	 each	case	activating	 the	EGFR	pathway	 in	
recipient	 cells	without	 chemotherapy	 or	 SASP	 engagement	 in	 the	
TME	 (Corrado	 et	 al.,	 2016;	 Raimondo	 et	 al.,	 2019;	 Taverna	 et	 al.,	
2017).	Through	in	vitro	assays,	we	revealed	that	AREG	is	one	of	the	
major	effectors	of	the	full	SASP	spectrum,	as	elimination	of	AREG	
from	stromal	cells	caused	substantially	weakened	cancer	cell	malig‐
nancies, including proliferation, migration, invasion, and more im‐
portantly chemoresistance. Of note, chemotherapy combined with 
an	AREG‐targeting	monoclonal	antibody	achieved	an	efficacy	 that	
was even higher than that generated by chemotherapy plus cetux‐
imab,	a	FDA‐approved	anti‐EGFR	agent,	suggesting	that	EGFR	may	
not	be	the	sole	cell	surface	receptor	interacted	by	paracrine	AREG	
in	the	TME	niche.	Thus,	future	studies	are	warranted	to	address	this	
interesting issue.
Although	largely	neglected	in	clinical	practice,	accumulating	ev‐
idence suggests that the efficacy of conventional anticancer agents 
not only involves direct cytotoxic and/or cytostatic effects, but also 
relies	 on	 the	 (re)activation	 of	 tumor‐targeting	 immune	 responses.	
Many chemotherapeutics can presumably promote such responses 
by enhancing the immunogenicity of cancer cells or through inhib‐
iting immunosuppressive circuitries established by developing tu‐
mors, as evidenced by the case of immunogenic chemotherapeutics 
that	cause	T‐cell	 infiltration	and	sensitize	tumors	to	ICB	(Pfirschke	
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et	 al.,	 2016).	 Such	 immunological	 “side”	 effects	 of	 chemotherapy	
are indeed desirable, and a thorough comprehension will facilitate 
the design of novel combinatorial regimens with improved clinical 
outcome.	 The	 clinical	 activity	 of	most,	 if	 not	 all,	 conventional	 an‐
ticancer agents currently licensed for use in human clinics can be 
attributed	to	the	re‐establishment	of	 immunosurveillance	 (Galluzzi	
et	 al.,	 2015).	Although	 former	 studies	 indicated	 the	production	of	
AREG	by	special	subsets	of	immune	cells	(Zaiss	et	al.,	2015,	2013),	
we	interrogated	the	immune	regulation	potential	of	AREG	as	a	SASP	
factor	 released	by	 the	damaged	TME,	and	explored	the	possibility	
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of developing combinatorial regimens with improved therapeutic 
profile. Intriguingly, the data showed that beyond the phenotypic 
changes	 in	cancer	cells,	 such	as	appearance	of	EMT,	and	develop‐
ment	 of	 CSC	 and	 ANG,	 which	 together	 constitute	 a	 unique	 EET	
pattern,	 significant	 upregulation	 of	 PD‐L1	 was	 observed	 upon	
co‐culture	with	 stromal	 cells	 either	 showing	 a	 full‐blown	 SASP	 or	
producing	exogenous	AREG.	More	importantly,	AREG	seems	to	be	
the	major	factor	of	the	full	SASP	spectrum	in	eliciting	such	immune	
checkpoint	 activation.	 Thus,	 in	 contrary	 to	 the	 well‐established	
concept	of	immunosurveillance	enhanced	by	the	SASP	(Kang	et	al.,	
2011;	Xue	et	al.,	2007),	our	findings	disclosed	an	 immunosuppres‐
sive	 function	 of	 the	 SASP	 manifested	 by	 the	 treatment‐damaged	
TME.	 Such	 an	 effect	 can	 be	mediated	 by	 certain	 factors	 such	 as	
AREG,	which	potently	induces	PD‐L1	expression	in	recipient	cancer	
cells	and	causes	exhaustion	of	CTL	and	NK	cells,	presumably	over‐
riding the net immunostimulatory capacity of senescent cells alone. 
We	thus	explored	the	feasibility	of	targeting	this	response	by	using	
therapeutic	 antibodies	 that	 specifically	 recognize	 either	 PD‐L1	 or	
its	 receptor,	 PD‐1,	 agents	 that	 block	 the	 immune	 checkpoint.	Our	
preclinical	studies	showed	that	such	an	ICB	treatment	was	more	ef‐
fective	 when	 synergizing	 with	 conventional	 chemotherapy,	 which	
causes	 irreparable	TME	damage	and	 induces	substantial	AREG	ex‐
pression in stromal compartments, resulting in the formation of an 
immunosuppressive	 niche	 via	 PD‐L1	 upregulation	 in	 cancer	 cells.	
Surprisingly,	 in	 contrast	 to	 the	 ICB	 agents	 approved	 for	 clinical	
purposes,	AREG	mAb	exhibited	even	higher	therapeutic	efficiency	
when combined with “classic” chemotherapeutics, a case observed 
in	both	PCa	and	BCa	animal	models	humanized	for	ICB	studies.	It	is	
reasonable to speculate that these effects are mediated simultane‐
ously	through	minimizing	chemoresistance	and	dampening	immune	
checkpoint	activation,	both	processes	orchestrated	by	the	paracrine	
AREG	in	an	immunocompetent	TME.
In clinical oncology, routine chemotherapy is compatible with 
an	 immune	 response,	 as	 experimental	 dendritic	 cell	 (DC)‐,	 DNA‐,	
or peptide‐based anticancer vaccines can elicit tumor‐targeting 
immune responses in patients treated with conventional chemother‐
apeutics	(Bloy	et	al.,	2014).	Chemotherapy	often	interacts	positively	
with	ICB‐based	immunotherapy.	For	instance,	ipilimumab	improves	
the efficacy of carboplatin/paclitaxel‐based chemotherapy in lung 
cancer,	while	oxaliplatin	boosts	anti‐PD‐L1	mAb	therapy	against	col‐
orectal	cancer	(Reck	et	al.,	2013;	Song	et	al.,	2018).	Specifically,	PD‐
L1	inhibitors,	including	a	locally	expressed	PD‐L1	trap	delivered	by	
lipid–protamine–DNA	nanoparticles,	hold	the	potential	 to	 improve	
cancer treatment index following oxaliplatin‐based chemotherapy 
(Song	et	al.,	2018).	However,	a	recent	study	addressing	the	impact	
of	chemotherapy	on	the	PD‐1/PD‐L1	pathway	revealed	that	5‐flu‐
orouracil/oxaliplatin	 (Folfox)	 induced	 complete	 and	 long‐term	 re‐
sponses	in	colorectal	cancer	mice	upon	combination	with	anti‐PD‐1	
treatment,	while	each	monotherapy	failed	(Dosset	et	al.,	2018).	The	
study	presented	a	link	between	Folfox‐triggered	immunogenic	can‐
cer	cell	death,	cancer	cell	PD‐L1	expression,	and	CD8+	T‐cell	infiltra‐
tion, raising the emerging concept that adaptive immune escape is a 
dominant mechanism of cancer resistance in the context of a patho‐
logically	activate	TME	(Ribas,	2015).	Thus,	recognizing	the	specific	
adaptive	 resistance	mechanisms	 is	 likely	 to	 favor	 the	personalized	
development of immunotherapies tailored to special conditions in 
cancer	clinics.	In	our	work,	the	SASP	potently	drives	therapeutic	re‐
sistance by not only enhancing the survival of cancer cells against 
chemotherapeutic	agents	but	also	consolidating	the	immune	check‐
point	potential	against	CTL	and	NK	cell	activities,	a	process	that	is	
mainly	mediated	by	a	soluble	factor	AREG.
ICB‐based	 immunotherapies	 can	be	extraordinarily	effective,	
but so far have benefited only a minority of patients whose tumors 
are	pre‐infiltrated	by	T	cells,	particularly	when	appropriately	 se‐
lected	immunogenic	drugs	(e.g.,	oxaliplatin	plus	cyclophosphamide	
for	 treatment	of	 tumors	expressing	oncogenic	KRAS	but	 lacking	
p53)	are	used	(Pfirschke	et	al.,	2016).	Our	study	indicates	that	the	
proportion of cancer cases responding to anticancer treatments 
can be feasibly and substantially expanded by combining con‐
ventional	 chemotherapies	 with	 ICB	 treatment,	 an	 effective	 and	
F I G U R E  7  AREG	is	a	novel	circulating	biomarker	of	in	vivo	SASP,	implies	immunosuppression,	and	predicts	adverse	therapeutic	outcome.	
(a)	Abundance	of	AREG	protein	in	the	serum	of	untreated	and	chemo‐treated	PCa	patients.	Data	were	derived	from	ELISA	measurement	
and	shown	as	mean	±	SD, n	=	20.	(b)	Abundance	of	IL‐8	protein	in	patient	serum	analyzed	in	(a).	Data	were	derived	from	ELISA	measurement	
and	presented	as	mean	±	SD, n	=	20.	(c)	Scatterplot	showing	correlation	between	AREG	and	IL‐8	in	the	serum	of	individual	patients	studied	
in	(a)	and	(b).	Pearson's	correlation	coefficient,	P	value,	and	confidence	interval	indicated.	(d)	Immunoblot	of	AREG	and	IL‐8	in	the	serum	of	
randomly	selected	PCa	patients	from	untreated	and	chemo‐treated	groups,	respectively	(n	=	4	for	untreated;	n	=	6	for	treated).	Albumin,	
sample	loading	control	for	patient	serum	protein.	(e)	Heatmap	depicting	the	overall	correlation	between	stromal	AREG,	stromal	IL‐8,	
serum	AREG,	and	serum	IL‐8	in	chemo‐treated	patients	(n	=	20).	The	raw	scores	of	stromal	AREG	and	IL‐8	were	derived	from	independent	
pathological	reading	of	primary	PCa	tissues,	while	scores	of	serum	AREG	and	IL‐8	came	from	ELISAs.	Color	key,	relative	expression	of	these	
two	factors	in	stromal	tissue	or	patient	serum.	(f)	Kaplan–Meier	survival	analysis	of	chemo‐treated	PCa	patients.	Disease‐free	survival	(DFS)	
stratified	according	to	AREG	expression	in	tumor	stroma	(low,	average	score	<2,	turquoise	line;	high,	average	score	≥2,	orange	line).	DFS	
represents	the	length	(months)	of	period	calculated	from	the	date	of	chemotherapy	completion	to	the	point	of	first‐time	disease	relapse.	
Survival	curves	generated	according	to	the	Kaplan–Meier	method,	with	p	value	calculated	using	a	log‐rank	(Mantel–Cox)	test.	n = 10 per 
group.	(g)	Multidimensional	TCGA	data	(bar	graph)	show	alterations	of	AREG	across	an	array	of	human	cancer	types	at	genomic	level,	
including	mutation,	amplification,	deep	deletion,	and	multiple	alterations.	Modification	frequency	is	displayed	in	percentage.	Data	were	
extracted	from	TCGA	database	followed	by	deep	analysis	with	cBioPortal	online	analyzing	tools.	(h)	Work	model	of	AREG	induction	in	
the	treatment‐damaged	TME,	pathological	impact	on	intercellular	signaling	network	of	cancer	cells,	immunosuppressive	consequence	by	
activation	of	immune	checkpoint	against	CTL/NK	cells,	and	the	potential	as	a	novel	circulating	biomarker	for	clinical	surveillance/prognosis.	
Data of a–d are representative of three independent experiments. P	values	were	calculated	by	Student's	t	test	(a,	b),	Pearson's	analysis	(c),	
and	log‐rank	test	(f)	(***p < .001 and ****p	<	.0001)
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promising	strategy	that	sensitizes	tumors	to	checkpoint	inhibitory	
agents	 and	 controls	 cancer	 durably	 by	 antagonizing	 the	 survival	
advantage	 conferred	 by	 a	 treatment‐remodeled	 TME.	 However,	
there	are	also	caveats	in	this	study.	First,	for	patients	with	EGFR	
mutations	 such	 as	 T790M	 in	 lung	 cancer,	 the	 efficacy	 of	 anti‐
AREG	may	be	restrained,	as	EGFR	downstream	signaling	network	
remains	 active.	 Second,	 cancer	 cell‐autonomous	 AREG	 expres‐
sion may occur in some tumor types, although not manifested by 
clinical	samples	(PCa	and	BCa)	investigated	by	our	study.	Beyond	
cancer	 cell‐expressed	 AREG	 in	 special	 cases,	 the	 TME‐derived	
AREG	 exerts	 an	 extra	 layer	 of	 chronic	 and	 long‐term	 pathologi‐
cal impacts on patients, including but not limited to development 
of	acquired	resistance	to	anti‐EGFR	therapies	such	as	cetuximab.	
However,	 targeting	 stroma‐derived	AREG	 represents	 an	 optimal	
therapeutic	effort	that	is	able	to	eliminate	AREG	produced	by	both	
stromal	 cells	 and	 cancer	 cells	 in	 the	 TME	 niche.	 Third,	we	 used	
PBMCs	from	donors	unrelated	to	the	patient	from	which	PC3	cells	
were originally derived. In such a case, it is reasonable to speculate 
ample	alloreactivity	based	on	the	recognition	of	MHC	alloantigens	
in	transplanted	tumors.	Though	this	experimental	setting	is	clearly	
not	maximally	mimicking	 the	 response	 against	 tumor‐associated	
neoantigens, our model permits a pharmacodynamic appraisal of 
in	vivo	effects	of	an	 immunostimulatory	or	a	single	SASP	factor‐
specific	mAb,	 thus	offering	valuable	mechanistic	 clues	 to	be	ex‐
plored by future research pipelines.
Understanding	 the	 immunomodulatory	 effects	 of	 conven‐
tional anticancer drugs may have a profound effect on the design 
of novel and optimal treatment options that allow these agents to 
be	combined	with	 immunotherapies	 (Galluzzi	et	al.,	2015).	There	
are two cases of combinatorial regimens in which immunotherapy 
can	markedly	improve	the	clinical	profile	of	anticancer	treatments,	
particularly chemotherapy. In the first scenario, immunotherapy 
may	be	harnessed	to	maximize	the	immunostimulatory	effects	of	
therapeutic	agents	such	as	 those	 reported	previously	 (Dosset	et	
al.,	2018;	Pfirschke	et	al.,	2016).	Second,	immunotherapy	may	be	
used	to	neutralize	the	unwarranted	immunosuppressive	effects	of	
anticancer	drugs,	particularly	those	mediated	by	the	TME	compo‐
nents as illustrated by our study. Each case, insightful understand‐
ing and successful harnessing of the currently approved anticancer 
drugs will permit to design more efficient and safer combinatorial 
therapies, and such a pragmatic strategy is believed to be able to 
present the best imaginable service to cancer patients in future 
practice.
4  | E XPERIMENTAL PROCEDURES
4.1 | Cell culture
Primary	normal	human	prostate	stromal	cell	line	PSC27	and	breast	
stromal	cell	line	HBF1203	were	maintained	in	stromal	complete	me‐
dium	as	described	(Sun	et	al.,	2012).	Prostate	cancer	epithelial	cell	
lines	PC3,	DU145,	and	LNCaP	and	breast	cancer	epithelial	cell	lines	
MCF7,	 MDA‐MB‐231,	 MDA‐MB‐468,	 T47D,	 and	 BT‐474	 (ATCC)	
were	routine	cultured	with	RPMI	1640	(10%	FBS).	BPH1	was	isolated	
from	prostatic	 tissue	with	benign	hyperplasia	and	 immortalized	by	
SV40‐LT	(Hayward	et	al.,	1995),	while	M12	was	derived	from	BPH1	
but	phenotypically	neoplastic	and	metastatic	 (Bae	et	al.,	1998).	All	
cell lines were routinely tested for mycoplasma contamination and 
authenticated	with	STR	assays.
4.2 | Stromal cell treatments
Stromal	 cells	were	 grown	 until	 80%	 confluent	 (CTRL)	 and	 treated	
with genotoxic agents 50 μg/ml	bleomycin	 (BLEO),	500	nM	mitox‐
antrone	 (MIT),	10	μM	satraplatin	 (SAT),	10	μM	doxorubicin	 (DOX),	
100 μM	 cisplatin	 (CIS),	 200	 μM	 carboplatin	 (CARB),	 0.6	 mM	 hy‐
drogen	peroxide	 (HP),	or	γ‐radiation by a 137Cs	source	at	743	rad/
min	 for	10	Gy	 (RAD).	Alternatively,	 cells	were	 treated	by	nongen‐
otoxic	chemicals	paclitaxel	 (10	nM,	PTX),	docetaxel	 (10	nM,	DTX),	
vincristine	 (20	nM,	VCR),	vinorelbine	 (20	nM,	VNB),	or	vinblastine	
(20	nM,	VBL).	After	treatment,	the	cells	were	rinsed	briefly	with	PBS	
and allowed to stay for 7–10 days prior to performance of various 
examinations.
4.3 | Cancer patient recruitment and 
biospecimen analysis
Chemotherapeutic	 administration	 involving	 genotoxic	 agents	
was	 performed	 for	 primary	 prostate	 cancer	 patients	 (clinical	 trial	
no.	 NCT03258320)	 and	 infiltrating	 ductal	 breast	 cancer	 patients	
(clinical	trial	no.	NCT02897700),	by	following	the	CONSORT	2010	
Statement	 (updated	 guidelines	 for	 reporting	 parallel	 group	 rand‐
omized	 trials).	Patients	with	a	 clinical	 stage	≥I	 subtype	A	 (IA;	T1a,	
N0,	M0)	of	primary	cancer	but	without	manifest	distant	metastasis	
were	enrolled	 into	the	multicentered,	 randomized,	double‐blinded,	
and	 controlled	 pilot	 studies.	 Age	 between	 40	 and	 75	 years	 with	
histologically	proven	prostate	cancer,	or	age	≥18	years	with	histo‐
logically	proven	infiltrating	ductal	breast	cancer,	was	required	for	re‐
cruitment into the individual clinical cohorts. Data regarding tumor 
size,	 histological	 type,	 tumor	 penetration,	 lymph	 node	metastasis,	
and	TNM	stage	were	obtained	from	the	pathologic	records.	Before	
chemotherapy,	 tumors	were	acquired	from	these	patients	as	 “Pre”	
samples	(an	“Untreated”	cohort).	After	chemotherapy,	remaining	tu‐
mors	in	patients	were	acquired	as	“Post”	samples	(a	“Chemo‐treated”	
cohort, with most tumors collected within 1–6 months after treat‐
ment).	 For	 some	 cases,	 the	 “Pre”	 and	 “Post”	 tumor	 biopsies	 from	
the same individual patient were both accessible, and these sam‐
ples	were	subject	to	further	evaluation.	Tumors	were	processed	as	
FFPE	biospecimens	and	sectioned	for	histological	assessment,	with	
alternatively	prepared	OCT‐frozen	chunks	processed	via	laser	cap‐
ture	microdissection	(LCM)	for	gene	expression	analysis.	Specifically,	
stromal compartments associated with glands and adjacent to can‐
cer epithelium were separately isolated from tumor biopsies before 
and	after	chemotherapy	using	an	Arcturus	(Veritas	Microdissection)	
laser	capture	microscope	following	previously	defined	criteria	(Sun	
et	al.,	2012).	The	immunoreactive	scoring	(IRS)	gives	a	range	of	1–4	
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qualitative	scores	according	to	staining	intensity	per	tissue	sample.	
Categories	for	the	IRS	include	0–1	(negative),	1–2	(weak),	2–3	(mod‐
erate),	and	3–4	(strong;	Fedchenko	&	Reifenrath,	2014).	The	diagno‐
sis of prostate cancer and breast cancer tissues was confirmed based 
on	histological	evaluation	by	independent	pathologists.	Randomized	
controlled	 trial	 (RCT)	 protocols	 and	 all	 experimental	 procedures	
were	 approved	 by	 the	 Ethics	 Committee	 and	 the	 Institutional	
Review	Board	of	Shanghai	Jiao	Tong	University	School	of	Medicine	
and	Zhongshan	Hospital	of	Fudan	University,	with	methods	carried	
out in accordance with the official guidelines. Informed consent 
was obtained from all subjects, and the experiments conformed to 
the	principles	set	out	 in	the	WMA	Declaration	of	Helsinki	and	the	
Department	of	Health	and	Human	Services	Belmont	Report.
4.4 | Histology and immunohistochemistry
Formalin‐fixed	paraffin‐embedded	tissue	sections	of	7	μm were de‐
paraffinized	in	xylenes	and	rehydrated	through	a	graded	series	of	al‐
cohols. Routine histology appraisal was performed with hematoxylin 
and	eosin	staining.	For	immunohistochemical	(IHC)	evaluation,	FFPE	
sections underwent antigen retrieval with sodium citrate, incuba‐
tion with 3% H2O2,	and	treatment	with	avidin/biotin	blocking	buffer	
(Vector	 Laboratories)	 and	 then	 3%	BSA	 for	 30	min.	 Staining	with	
primary	and	secondary	antibodies	was	conducted	at	4°C	for	over‐
night and at room temperature for 60 min, respectively. Sections 
were incubated with a H2O2‐diaminobenzidine	 (DAB)	substrate	kit	
(Vector,	SK‐4100).	Samples	were	counterstained	with	hematoxylin,	
dehydrated,	and	mounted.	IHC	images	were	obtained	using	an	up‐
right	microscope	(Olympus	BX51).	Brown	staining	indicated	the	im‐
munoreactivity of samples.
4.5 | In vivo SASP assessment of 
patients and ELISAs
Sections of clinical biospecimens or animal tissues were processed 
via	 LCM	 for	 gene	 expression	 analysis.	 Specifically,	 stromal	 com‐
partments associated with glands in patient tumor samples were 
separately	isolated	using	an	Arcturus	(Veritas	Microdissection)	laser	
capture	microscope	following	the	criteria	defined	formerly	 (Sun	et	
al.,	2012).	For	tumors	grown	from	xenografts	composed	of	human	
cells,	OCT	sections	were	 first	H&E‐stained	 to	determine	 the	 loca‐
tion of stromal cells and the stroma–epithelium border; then, cell 
lineages	 were	 separately	 acquired	 by	 LCM.	 Transcript	 levels	 of	
human	SASP	canonical	factors	including	IL‐6,	IL‐8,	WNT16B,	SFRP2,	
MMP1,	MMP3,	and	MMP10	were	measured	by	qRT–PCR	(primers	
listed	in	Table	S6).
Peripheral	blood	samples	from	cancer	individuals	with	matched	
FFPE	or	frozen	tumor	samples	were	collected	in	EDTA‐	or	heparin‐
coated tubes and centrifuged at 2,000 g for 10 min at room tempera‐
ture	within	1	hr	of	clinical	acquisition	to	prepare	high‐quality	serum.	
AREG	and	IL‐8	proteins	in	serum	of	cancer	patients	were	subject	to	
quantification	by	antigen‐specific	ELISA	kits	(R&D	Systems,	DAR00/
DY208)	according	to	the	manufacturer's	instructions.	Detection	lim‐
its	for	these	factors	were	20	and	40	pg/ml,	respectively.
4.6 | Immunodeficient animals and 
preclinical studies
All	animals	were	maintained	in	a	specific	pathogen‐free	(SPF)	facil‐
ity,	with	NOD/SCID	(Charles	River	and	Nanjing	Biomedical	Research	
Institute	of	Nanjing	University)	mice	at	an	age	of	~6	weeks	 (~20	g	
body	weight)	used.	Ten	mice	were	incorporated	in	each	group,	and	
xenografts	were	subcutaneously	generated	at	 the	hind	flank	upon	
anesthesia	mediated	by	 isoflurane	 inhalation.	Stromal	cells	 (PSC27	
or	HBF1203)	were	mixed	with	cancer	cells	 (PC3,	LNCaP,	or	MDA‐
MB‐231)	at	a	ratio	of	1:4	 (i.e.,	250,000	stromal	cells	admixed	with	
1,000,000	cancer	cells	to	make	tissue	recombinants	before	implan‐
tation	 in	 vivo).	 Animals	were	 sacrificed	 at	 2–8	weeks	 after	 tumor	
xenografting,	 according	 to	 tumor	burden	or	 experimental	 require‐
ments.	 Tumor	 growth	was	monitored	weekly,	 with	 tumor	 volume	
(v)	measured	and	calculated	according	to	the	tumor	length	(l),	width	
(w),	and	height	(h)	by	the	formula:	v	=	(π/6)	×	((l	+	w	+	h)/3)3.	Freshly	
dissected	tumors	were	either	snap‐frozen	or	fixed	to	prepare	FFPE	
samples.	Resulting	sections	were	used	for	IHC	staining	against	spe‐
cific antigens or subject to hematoxylin/eosin staining.
For	 chemoresistance	 studies,	 animals	 received	 subcutaneous	
implantation of tissue recombinants as described above and were 
given	standard	laboratory	diets	for	2	weeks	to	allow	tumor	uptake	
and	growth	initiation.	Starting	from	the	3rd	week	(tumors	reaching	
4–8	 mm	 in	 diameter),	 MIT	 (0.2	 mg/kg	 doses),	 DOX	 (doxorubicin,	
1.0	mg/kg	doses),	therapeutic	antibodies	(cetuximab	or	AREG	mAb,	
10.0	mg/kg	doses,	200	μl/dose),	or	vehicle	controls	were	adminis‐
tered	 by	 body	 injection	 (chemicals	 via	 intraperitoneal	 route,	 anti‐
bodies	through	tail	vein),	on	the	1st	day	of	3rd,	5th,	and	7th	weeks,	
respectively.	Upon	completion	of	the	8‐week	therapeutic	regimen,	
animals were sacrificed, with tumor volumes recorded and tissues 
processed for histological evaluation.
At	the	end	of	chemotherapy	and/or	targeting	treatment,	animals	
were	anaesthetized	and	peripheral	blood	was	gathered	via	cardiac	
puncture.	Blood	was	transferred	into	a	1.5‐ml	Eppendorf	tube	and	
kept	 on	 ice	 for	 45	 min,	 followed	 by	 centrifugation	 at	 5,800 g for 
10	min	at	4°C.	Clear	supernatants	containing	serum	were	collected	
and	transferred	into	a	sterile	1.5‐ml	Eppendorf	tube.	All	serum	mark‐
ers	 were	measured	 using	 dry‐slide	 technology	 on	 IDEXX	 VetTest	
8008	chemistry	analyzer	(IDEXX).	About	50	μl of the serum sample 
was	loaded	on	the	VetTest	pipette	tip	followed	by	securely	fitting	it	
on	the	pipettor,	and	the	manufacturer's	instructions	were	followed	
for further examination.
All	 animal	 experiments	 were	 performed	 in	 compliance	 with	
NIH	Guide	 for	 the	Care	 and	Use	 of	 Laboratory	Animals	 (National	
Academies	Press,	2011)	 and	 the	ARRIVE	guidelines,	 and	were	ap‐
proved	by	the	Institutional	Animal	Care	and	Use	Committee	(IACUC)	
of	the	University	of	Washington	or	Shanghai	Institutes	for	Biological	
Sciences,	Chinese	Academy	of	Sciences.
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4.7 | Immune checkpoint blockade assays, 
human peripheral blood mononuclear cells, and 
humanized mice
Atezolizumab	 (a	 selective	 humanized	 monoclonal	 IgG1	 antibody	
against	PD‐L1),	nivolumab	(a	humanized	IgG4	anti‐human	PD‐1),	and	
corresponding	human	IgG1	or	 IgG4	as	an	 isotype‐matched	control	
(MCE)	were	used	as	therapeutic	antibodies.	Peripheral	blood	mon‐
onuclear	cells	 (PBMCs)	were	 isolated	 from	10	ml	 freshly	collected	
clinical	 blood	 samples	 (approved	 by	 Institutional	 Review	Board	 of	
Zhongshan	Hospital	of	Fudan	University,	with	informed	consent	ob‐
tained	from	all	subjects).
Stromal	CM	was	harvested	 from	PSC27,	PSC27‐BLEO,	PSC27‐
shRNAC‐BLEO,	 PSC27‐shRNAAREG#1‐BLEO,	 and	 PSC27‐shR‐
NAAREG#2‐BLEO.	Approximately	200,000	prostate	cancer	cells	were	
seeded	in	6‐well	plates	and	subsequently	cultured	with	stromal	CM	
for	2	days.	PD‐L1/PD‐L2	protein	levels	in	prostate	cancer	cells	were	
determined	 by	 immunoblots.	 Prostate	 cancer	 cells	 were	 alterna‐
tively	treated	with	SB203580	(20	μM),	erlotinib	(100	nM),	AG1478	
(6	 μM),	 LY294002	 (4	 μM),	 MK2206	 (5	 μM),	 rapamycin	 (200	 nM),	
PD0325901	(500	nM),	Bay	11‐7082	(2	μM),	or	ruxolitinib	(10	μM)	for	
3	hr.	Subsequently,	prostate	cancer	cells	were	cultured	with	stromal	
CM	supplemented	with	each	inhibitor	for	2	days,	before	immunoblot	
assessment	of	PD‐L1	expression.	Freshly	isolated	and	Ficoll‐purified	
(STEMCELL,	 #07851)	 human	 peripheral	 blood	 mononuclear	 cells	
(PBMCs)	were	cultured	with	stromal	cell	CM	for	2	days,	with	PD‐1	
protein	expression	analyzed	with	immunoblot.
Peripheral	 blood	mononuclear	 cells	were	 also	 cultured	 in	RPMI	
1640	media	and	activated	by	500	U/ml	IL‐2	(Novus,	27095‐1‐AP)	for	
3	days.	Prostate	cancer	cells	were	cultured	with	stromal	cell	CM	for	
2	days	before	100,000	cells	were	seeded	in	24‐well	plates.	After	the	
prostate	cancer	cells	adhered	to	the	wall,	1,000,000	activated	PBMCs	
were	 added	 and	 co‐culture	 was	 maintained	 for	 2	 days.	 Levitated	
PBMCs	were	subject	to	PBS	wash	for	twice,	and	the	number	of	ad‐
herent prostate cancer cells was determined by hemocytometer.
Three‐	to	4‐week‐old	Rag2−/−IL2Rγnull	mice	(Jackson	Laboratory)	
were	 injected	with	 7	 ×	 106	 fresh	 human	 PBMCs	 via	 tail	 (i.v.)	 vein	
3	days	before	tumor	implantation,	when	a	total	of	1.2	×	106	PC3	cells	
were	injected	alone	or	together	with	0.3	×	106	PSC27	cells	subcuta‐
neously	(s.c.)	into	the	flank	of	Rag2−/−IL2Rγnull	mice.	At	the	beginning	
of	the	3rd	week,	a	time	point	when	implanted	cells	were	stably	ab‐
sorbed,	animals	were	treated	with	atezolizumab	(or	nivolumab,	each	
controlled	by	an	isotype‐matched	immunoglobulin,	IgG1	for	atezoli‐
zumab,	IgG4	for	nivolumab)	alone	or	with	AREG	mAb	(200	μl/dose)	
via	i.v.	injection.	Mitoxantrone	(MIT)‐based	chemotherapy	(0.2	mg/
kg/dose)	was	performed	on	the	same	day	of	antibody	injection,	with	
the administration conducted on the 1st day of 3rd, 5th, and 7th 
weeks,	respectively.	These	PBMC‐injected	mice	were	bi‐weekly	ex‐
amined	via	the	retro‐orbital	route	for	human	CD45+	cells	in	the	pe‐
ripheral	blood,	with	a	minimal	of	25%	human	CD45+	cells	considered	
qualified	 human	 PBMC‐circulating	 animal	 models.	 Blood	 samples	
were	also	evaluated	for	the	concentration	of	human	IFN‐γ	and	TNF‐α 
in	plasma	by	antigen‐specific	ELISA	(BD	Biosciences	and	PeproTech,	
detection	cutoff	per	assay	5.0	pg/ml	 for	 IFN‐γ and 15.0 pg/ml for 
TNF‐α,	 respectively).	Upon	 completion	 of	 the	 8‐week	 therapeutic	
regimen, animals were sacrificed, with tumor volumes recorded and 
tissues subject to further assessment. Specifically, tumor‐infiltrating 
lymphocytes from each treatment group were assayed by flow cy‐
tometry,	with	number	of	human	CD8+	T	cells	and	regulator	T	cells	
per mg of tumor determined.
4.8 | Statistical analysis
All	in	vitro	experiments	were	performed	in	triplicates,	and	animal	stud‐
ies were conducted with n	≥	8	mice	per	group.	Sample	sizes	were	es‐
timated based on an 80% power to detect a 50% reduction in tumor 
volumes observed in mice subject to chemotherapy compared with 
control	mice,	accepted	a	type	I	error	rate	of	0.05.	Animals	were	dis‐
tributed	 into	groups	of	equal	body	weight,	and	no	animals	were	ex‐
cluded	from	analysis.	Unless	otherwise	indicated,	data	in	the	figures	
were	presented	as	mean	±	SD.	Univariate	and	multivariate	Cox	propor‐
tional	hazard	model	analyses	were	performed	with	statistical	software	
SPSS.	Statistical	significance	was	determined	by	unpaired	two‐tailed	
Student's	t	test,	one‐	or	two‐way	ANOVA,	nonlinear	dose–response	
fitting	curve	for	IC50	calculation	with	GraphPad	Prism	5.0,	Pearson's	
correlation	 coefficient	 test,	 Kruskal–Wallis	 test,	 Kaplan–Meier	 (log‐
rank)	test,	Wilcoxon–Mann–Whitney	test,	or	Fisher's	exact	test.	For	
all statistical tests, a p value <.05 was considered significant.
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